Alteration of Tobacco Alkaloid Content through Modification of Specific Cytochrome P450 Genes by Dewey, Ralph E. et al.
University of Kentucky
UKnowledge
Plant and Soil Sciences Faculty Patents Plant and Soil Sciences
2-28-2012
Alteration of Tobacco Alkaloid Content through







Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/pss_patents
Part of the Plant Sciences Commons
This Patent is brought to you for free and open access by the Plant and Soil Sciences at UKnowledge. It has been accepted for inclusion in Plant and Soil
Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Recommended Citation
Dewey, Ralph E.; Siminszky, Balaz; Bowen, Steven W.; and Gavilano, Lily, "Alteration of Tobacco Alkaloid Content through
Modification of Specific Cytochrome P450 Genes" (2012). Plant and Soil Sciences Faculty Patents. 6.
https://uknowledge.uky.edu/pss_patents/6
US008124851B2 
(12) United States Patent (10) Patent No.: US 8,124,851 B2 
Dewey et al. (45) Date of Patent: Feb. 28, 2012 
(54) ALTERATION OF TOBACCO ALKALOID OTHER PUBLICATIONS 
CONTENT THROUGH MODIFICATION OF . 
SPECIFIC CYTOCHROME P450 GENES EMBL Database Report for Accession No. DQ350312, Dec. 31, 
2006 (XP002511577). 
EMBLD t b R Itf A ' N .EU182719 D .2 2007 (75) Inventors: Ralph E. Dewey, Apex, NC (US); (XPOOZS $172163; epo or Ccesslon O ’ ec ’ 
Balazs Siminszky, Neuchatel (CH); 
Steven W. Bowen, Raleigh, NC (US); 
Lily Gavilano, Raleigh, NC (US) 
(73) Assignees: North Carolina State University, 
Raleigh, NC (U S); University of 
Kentucky Research Foundation, 
Lexington, KY (U S) 
( * ) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 316 days. 
(21) App1.No.: 12/269,531 
(22) Filed: Nov. 12, 2008 
(65) Prior Publication Data 
US 2009/0205072 A1 Aug. 13, 2009 
Related US. Application Data 
(60) Provisional application No. 60/987,243, ?led on Nov. 
12, 2007. 
(51) Int. Cl. 
C12N15/82 (2006.01) 
C12N 15/29 (2006.01) 
(52) US. Cl. .................................. .. 800/317.3; 536/245 
(58) Field of Classi?cation Search ...................... .. None 
See application ?le for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
5,668,295 A 9/1997 Wahab et al. 
5,684,241 A 11/1997 Nakataniet al. 
2004/0103449 A1 5/2004 Xu 
2004/0111759 A1 6/2004 Xu 
2004/0117869 A1 6/2004 Xu 
2004/0162420 A1 8/2004 Xu 
2005/0132444 A1 6/2005 Xu 
2005/0223442 A1* 10/2005 Xu ........................... .. 800/3173 
2006/0037096 A1 2/2006 Xu 
FOREIGN PATENT DOCUMENTS 
W0 WO 00/67558 A1 11/2000 
W0 W0 03/078577 A2 9/2003 
W0 WO 2004/035745 A2 4/2004 
W0 WO 2005/038018 A2 4/2005 
W0 WO 2005/038033 A2 4/2005 
W0 WO 2005/111217 A2 11/2005 
W0 WO 2005/116199 A2 12/2005 
W0 WO 2006/091194 A1 8/2006 
Chakrabarti, M., et al., “Inactivation of teh Cytochrome P450 Gene 
CYP82E2 by Degenerative Mutations Was a Key Event in the Evol 
lution of the Alkaloid Pro?le of Modern Tobacco,” New Phytol., May 
30, 2007, pp. 565-574, vol. 175, No. 3. 
Gavilano, L.B., et al., “Genetic Engineering of Nicotiana tabacum 
for Reduced Nornicotine Content,” J'. Agric. Food Chem., Jul. 11, 
2006, pp. 9071-9078, vol. 54, No. 24. 
Gavilano, L.B., & B. Siminszky, “Isolation and Characterization of 
the Cytochrome P450 Gene CYP82E5v2 That Mediates Nicotine to 
Nornicotine Conversion in the Green Leaves of Tobacco,” Plant Cell 
Physiol., Oct. 8, 2007. pp. 1567-1574, vol. 48, No. 11. 
Gavilano, L.B., et al., “Functional Analysis of Nicotine Demethylas 
Genes Reveals Insights into the Evolution of Modern Tobacco,” J'. 
Biol. Chem, Jan. 5, 2007, pp. 249-256, vol. 282, No. 1. 
Siminszky, B., et al., “Conversion of Nicotine to Nornicotine in 
Nicotiana tabacum is Mediated by CYP82E4, a Cytochrome P450 
Monooxygenase,”PNAS, Oct. 11, 2005, pp. 14919-14924, vol. 102, 
No. 41. 
Chintapakorn, Y., et al., “Antisense-Mediated Down-Regulation of 
Putrescine N-Methyltransferase Activity in Transgenic Nicotiana 
Tabacum L. Can Lead to Elevated Levels of Anatabine at the Expense 
ofNicotine,” Plant Molecular Biology, 2003, pp. 87-105, vol. 53. 
Tang & Galili, “Using RNAi to Improve Plant Nutritional Value: 
From Mechanism to Application,” Trends in Biotechnology, 2004, 
pp. 463-469, vol. 22, No. 9. 
Gavilano, Lily B., “Isolation, Cloning and Characterization of Novel 
Tobacco Cytochrome P450 Genes Involved in Secondary Metabo 
lism,” Plant Biology Meeting, Jul. 24-28, 2004, Lake Buena Vista, 
Florida, Abstract No. 992, Retrieved from the Internet: URL: http:// 
abstracts.aspb.org/pb2004/public/P75/8027.html. 
* cited by examiner 
Primary Examiner * Anne Kubelik 
(74) Attorney, Agent, or Firm * Alston & Bird LLP 
(57) ABSTRACT 
Compositions and methods for reducing the level of nomico 
tine and N'-nitrosonornicotine (NNN) inNicotiana plants and 
plant parts thereof are provided. The compositions comprise 
isolated polynucleotides and polypeptides for cytochrome 
P450s that are involved in the metabolic conversion of nico 
tine to nornicotine in these plants. Expression cassettes, vec 
tors, plants, and plant parts thereof comprising inhibitory 
sequences that target expression or function of the disclosed 
cytochrome P450 polypeptides are also provided. Methods 
for the use of these novel sequences to inhibit expression or 
function of cytochrome P450 polypeptides involved in this 
metabolic conversion are also provided. The methods ?nduse 
in the production of tobacco products that have reduced levels 
of nornicotine and its carcinogenic metabolite, NNN, and 
thus reduced carcinogenic potential for individuals consum 
ing these tobacco products or exposed to secondary smoke 
derived from these products. 
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ALTERATION OF TOBACCO ALKALOID 
CONTENT THROUGH MODIFICATION OF 
SPECIFIC CYTOCHROME P450 GENES 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the bene?t of US. Provisional 
Application No. 60/987,243, ?led Nov. 12, 2007, the content 
of Which is hereby incorporated in its entirety by reference 
herein. 
REFERENCE TO SEQUENCE LISTING 
SUBMITTED ELECTRONICALLY 
An of?cial copy of the Sequence Listing is submitted elec 
tronically via EFS-Web as an ASCII formatted Sequence 
Listing With a ?le named “362493SequenceListing.txt,” cre 
ated on Nov. 11, 2008, and having a siZe of 137 kb and is ?led 
concurrently With the speci?cation. The Sequence Listing 
contained in this ASCII formatted document is part of the 
speci?cation and is herein incorporated by reference in its 
entirety. 
FIELD OF THE INVENTION 
The present invention relates to compositions and methods 
for reducing the level of nornicotine and its metabolite, N'-ni 
trosonornicotine (NNN), in a plant that is a member of the 
genus Nicoliana, particularly compositions and methods for 
inhibiting expression or function of a cytochrome P450 
polypeptide involved in the metabolic conversion of nicotine 
to nomicotine. 
BACKGROUND OF THE INVENTION 
A predominant alkaloid found in commercial tobacco vari 
eties is nicotine, typically accounting for 90%-95% of the 
total alkaloid pool. The remaining alkaloid fraction is prima 
rily three additional pyridine alkaloids: nomicotine, ana 
basine and anatabine. Nomicotine is generated directly from 
nicotine by nicotine N-demethylase. Nomicotine usually rep 
resents less than 5% of the total pyridine alkaloid pool. HoW 
ever, tobacco plants that initially produce very loW amounts 
of nornicotine can give rise to progeny that metabolically 
“convert” a large percentage of leaf nicotine to nomicotine. 
This process is termed “conversion.” In tobacco plants that 
have genetically converted (i.e., “converters”), the great 
majority of nornicotine production occurs during senescence 
and curing of a mature leaf (Wemsman & MatZinger (1968) 
Tob. Sci. 12:226-228). Burley tobaccos are particularly prone 
to genetic conversion, With rates as high as 20% per genera 
tion observed in some cultivars. 
During curing and processing of the tobacco leaf, a portion 
of the nornicotine is metaboliZed to NNN, a tobacco-speci?c 
nitrosamine (TSNA) alleged to be carcinogenic in laboratory 
animals (Hecht & Hoffmann (1990) Cancer Surveys 8:273 
294; and Hoffmann et al. (1994) J. Toxicol. Environ. Health 
41:1-52; Hecht (1998) Chem. Res. Toxicol. 11:559-603). In 
?ue-cured tobaccos, TSNAs predominantly form through a 
reaction of alkaloids With minute amounts of nitrogen oxides 
present in combustion gases in a direct-?red heating systems 
used in traditional curing barns (Peele & Gentry (1999) “For 
mation of tobacco-speci?c nitrosamines in ?ue-cured 
tobacco,” CORESTA Meeting, Agro-Phyto Groups, SuZhou, 
China). The combustion gases, hoWever, can be eliminated 












Which eliminate the mixing of combustion gases With curing 
air, thereby reducing TSNAs in tobaccos cured in this manner 
(Boyette & Hamm (2001) Rec. Adv. Tob. Sci. 27:17-22.). In 
contrast, in air-cured Burley tobaccos, TSNA formation pri 
marily proceeds through a reaction of tobacco alkaloids With 
nitrite, a process catalyZed by leaf-borne microbes (Bush et 
al. (2001) Rec. Adv. Tob. Sci. 27:23-46). Thus far, attempts to 
reduce TSNAs through modi?cation of curing conditions 
While maintaining acceptable quality standards have not been 
successful for air-cured tobaccos. 
In Burley tobacco plants, a positive correlation exists 
betWeen the nornicotine content of a leaf and an amount of 
NNN that accumulates in the cured leaf (Bush et al. (2001) 
Rec. Adv. Tob. Sci, 27:23-46; and Shi et al. (2000) Tob. Chem. 
Res. Conf 54: Abstract 27). HoWever, keeping nornicotine 
levels at a minimum is dif?cult in Burley tobacco plants 
because of conversion. Plant breeders and seed producers are 
traditionally responsible for minimiZing the number of Bur 
ley tobacco plants that accumulate high levels of nomicotine. 
Though the percentage of converters that are ultimately 
groWn in ?elds are reduced through roguing converters during 
propagation of seed stocks. Unfortunately, this process is 
costly, time-consuming and imperfect. 
Once a plant converts, the high nornicotine trait is inherited 
as a single dominant gene (Grif?th et al. (1955) Science 
121:343-344; Burke & Jeffrey (1958) Tob. Sci. 2:139-141; 
and Man et al. (1964) Crop Sci. 4:349-353). The nature ofthis 
gene, hoWever, is currently unknoWn. In the simplest of sce 
narios, the conversion locus may represent a nonfunctional 
nicotine N-demethylase gene that regains its function in con 
verters, possibly through the mobilization of a mutation-in 
ducting transposable element. Alternatively, the converter 
locus may encode a protein that initiates a cascade of events 
that ultimately enables converters to metaboliZe nicotine to 
nornicotine, meaning that multiple genes may be involved. 
Regardless of Whether there are one or many genes asso 
ciated With conversion, the gene(s) encoding polypeptides 
having nicotine demethylase activity play a pivotal role in this 
process. Although the inability to purify active nicotine 
N-demethylase from crude extracts has impeded the isolation 
and identi?cation of this enzyme, there is some evidence that 
a member of the cytochrome P450 superfamily of monooxy 
genases may be involved (Hao &Yeoman (1996)Phylochem. 
41:477-482; Hao &Yeoman (1996) Phylochem. 42:325-329; 
Chelvarajan et al. (1993) .1. Agric, Food Chem. 41:858-862; 
and Hao & Yeoman (1998) .1. Plant Physiol. 152:420-426). 
Unfortunately, these studies are not conclusive, as classic 
P450 inhibitors, such as carbon monoxide and tetcylasis, fail 
to loWer enZyme activity at rates comparable to other reported 
P450-mediated reactions (Chelvarajan et al. (1993) J. A gric. 
Food Chem. 41:858-862). 
Furthermore, cytochrome P450s are ubiquitous, trans 
membrane proteins that participate in metaboliZing a Wide 
range of compounds (revieWed by Schuler (1996) Cril. Rev 
Plant Sci. 15:235-284; and Schuler & Werck-Reichhart 
(2003) Annu. Rev Plant Biol. 54:629-667). Examples ofbio 
chemical reactions mediated by cytochrome P450s include 
hydroxylations, demethylations and epoxidations. In plants, 
cytochrome P450 gene families are very large. For example, 
total genome sequence examination revealed 272 predicted 
cytochrome P450 genes in Arabidopsis and at least 455 
unique cytochrome P450 genes in rice (see, e.g., Nelson et al. 
(2004) Plant Physiol. 135(2):756-772). Even though cyto 
chrome P450s have been implicated in the conversion of 
nicotine to nomicotine, identi?cation of key participating 
members of this protein family remains a challenge. 
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Aside from serving as a precursor for NNN, recent studies 
suggest that the nornicotine found in tobacco products has 
undesirable health consequences. For example, Dickerson & 
Janda demonstrated that nornicotine causes aberrant protein 
glycosylation Within a cell (Dickerson & Janda (2002) Proc. 
Natl. Acad. Sci. USA 99: 15084-15088). Likewise, concentra 
tions of nornicotine-modi?ed proteins Were much higher in 
plasma of smokers compared to nonsmokers. Furthermore, 
nornicotine can covalently modify commonly prescribed ste 
roid drugs such as prednisone, Which can alter both the e?i 
cacy and toxicity of these drugs. 
In vieW of the di?iculties associated With conversion, as 
Well as the undesirable health effects of nornicotine accumu 
lation, improved methods for reducing the nornicotine con 
tent in tobacco varieties, particularly Burley tobacco plants, 
are therefore desirable. Such methods Would not only help 
ameliorate the potential negative health consequences of the 
nornicotine per se as described above, but also help to reduce 
NNN levels. 
SUMMARY OF THE INVENTION 
Compositions and methods are provided for reducing the 
nornicotine content in plants that are members of the genus 
Nicoliana. Compositions include isolated cytochrome P450 
polynucleotides and polypeptides that are involved in conver 
sion of nicotine to nornicotine in plants, particularly Nicoti 
ana species. Isolated polynucleotides include those that com 
prise a nucleic acid sequence as set forth in SEQ ID N01 1, 3 
or 4, a nucleic acid sequence encoding a polypeptide as set 
forth in SEQ ID N012, 5-12, 14-24, and fragments and vari 
ants thereof. Isolated polypeptides of the invention include 
those that comprise an amino acid sequence as set forth in 
SEQ ID N012, 5-12 or 14-24, an amino acid sequence 
encoded by the nucleic acid sequence set forth in SEQ ID N01 
1, 3 or 4, and fragments and variants thereof. 
In a ?rst aspect, the present invention is summarized as 
polynucleotides that can suppress expression of a nicotine 
demethylase involved in the metabolic conversion of nicotine 
to nornicotine in a plant, including the nicotine demethylases 
of the present invention. The present invention provides an 
isolated polynucleotide having a promoter capable of func 
tioning in a plant cell operably linked to a nucleic acid 
sequence comprising a region of betWeen about 100 nucleic 
acids and about 350 nucleic acids of SEQ ID N01 1 obtained 
from a sequence selected from the group of nucleic acids at 
position 253, 353, 647, 733, 1050, 1397 and combinations 
thereof. The present invention also provides an isolated poly 
nucleotide comprising a nucleic acid sequence encoding a 
green-leaf nicotine demethylase, Where the amino acid 
sequence of the encoded nicotine demethylase has a substi 
tution at an amino acid residue in a position selected from the 
group consisting ofresidues 235, 449, 174, 410, 224, 72, 143 
and 422, Where the numbering is according to SEQ ID N012. 
Also provided is an isolated polynucleotide comprising a 
promoter capable of functioning in a plant cell operably 
linked to a nucleic acid sequence comprising a region of 
betWeen about 100 nucleic acids and about 350 nucleic acids 
of SEQ ID N014. Further provided is an isolated polynucle 
otide encoding an amino acid sequence as set forth in SEQ ID 
N012 With a mutation of a residue that differs from the other 
P450 polypeptides to a conserved residue. Alternatively pro 
vided is an isolated polynucleotide encoding an amino acid 
sequence as set forth in SEQ ID N012 With a mutation at a 
position selected from the group consisting of residues 85, 
118, 216, 245 and 466, Where the residue at 85 is not an 












at 216 is not tyrosine, the residue at 245 is not a tyrosine, and 
the residue at 466 is not valine. 
In a second aspect, the present invention is summariZed as 
an expression cassette comprising a polynucleotide encoding 
an amino acid sequence of SEQ ID N012 operably linked to 
a promoter that is functional in a plant cell. The present 
invention provides an expression cassette comprises a poly 
nucleotide comprising a nucleic acid sequence of SEQ ID 
N013, or a fragment of at least 25 contiguous nucleic acids 
thereof, operably linked to a promoter that is functional in a 
plant cell. Also provided is an isolated polynucleotide com 
prising at least 25 nucleotides of a nucleic acid sequence of 
SEQ ID N013. Further provided is an isolated polypeptide 
comprising an amino acid sequence selected from the group 
consisting of SEQ ID N012, 5-12 and 14-24. In one embodi 
ment of the second aspect, the isolated polypeptide comprises 
an amino acid sequence 99% identical to SEQ ID N012, such 
that it is capable of converting nicotine to nornicotine in green 
leaves of tobacco. 
In a third aspect, the present invention is summariZed as a 
plant of the genus Nicoliana or a plant part thereof comprising 
an expression cassette, the cassette encoding SEQ ID N012, a 
fragment thereof, or a complement of either. Also provided is 
a transgenic Nicoliana plant having a loWer level of nicotine 
to nornicotine conversion rate in green leaves compared to a 
non-transgenic plant, the plant comprising an exogenous 
nucleic acid construct comprising a promoter capable of 
functioning in a plant cell operably linked to a polynucleotide 
having a ?rst nucleic acid sequence comprising a region of 
betWeen about 100 nucleic acids and about 350 nucleic acids 
of a green-leaf tobacco nicotine demethylase sequence 
encoding an amino acid sequence of SEQ ID N012 and a 
second nucleic acid sequence capable of forming a double 
stranded RNA With the ?rst sequence. Further provided is a 
transgenic Nicoliana plant having a loWer level of nicotine to 
nornicotine conversion rate in green leaves compared to a 
non-transgenic plant, the plant comprising an exogenous 
nucleic acid construct comprising a promoter capable of 
functioning in a plant cell operably linked to a polynucleotide 
having a ?rst nucleic acid sequence comprising a region of 
betWeen about 100 nucleic acids and about 350 nucleic acids 
of a green-leaf tobacco nicotine demethylase sequence hav 
ing the nucleic acid sequence of SEQ ID N013 and a second 
nucleic acid sequence capable of forming a double stranded 
RNA With the ?rst sequence is provided. Also provided is a 
transgenic Nicoliana plant having a loWer level of nicotine to 
nornicotine conversion rate in green leaves compared to a 
non-transgenic plant, the plant comprising an exogenous 
nucleic acid construct comprising a promoter capable of 
functioning in a plant cell operably linked to a polynucleotide 
having a ?rst nucleic acid sequence comprising a region of 
betWeen about 100 nucleic acids and about 350 nucleic acids 
of a green-leaf tobacco nicotine demethylase sequence hav 
ing a nucleic acid sequence of SEQ ID N014 and a second 
nucleic acid sequence capable of forming a double stranded 
RNA With the ?rst sequence. 
In a fourth aspect, the present invention is summariZed as a 
seed of a transgenic Nicoliana plant having a loWer level of 
nicotine to nornicotine conversion rate in green leaves com 
pared to a non-transgenic plant, the plant comprising a heter 
ologous promoter capable of functioning in a plant cell oper 
ably linked to a polynucleotide having a ?rst nucleic acid 
sequence comprising a region of betWeen about 100 nucleic 
acids and about 350 nucleic acids of a green-leaf tobacco 
nicotine demethylase sequence having an amino acid 
sequence of SEQ ID N014 and a second nucleic acid 
sequence capable of forming a double stranded RNA With the 
US 8,124,851 B2 
5 
?rst sequence. Also provided is a tissue culture of regenerable 
tobacco cells comprising a plant cell that comprises a ?rst 
polynucleotide having a fragment of the nucleic acid 
sequence of SEQ ID NO: 1, 3 or 4 and a second polynucle 
otide capable of forming a double stranded RNA With the 
?rst. 
In a ?fth aspect, the present invention is summarized as a 
tobacco product comprising a transgenic Nicoliana plant cell 
having a loWer level of nicotine to nomicotine conversion rate 
in green leaves compared to a non-transgenic plant, the plant 
cell comprising a heterologous promoter capable of function 
ing in a plant cell operably linked to a polynucleotide having 
a ?rst nucleic acid sequence comprising a region of betWeen 
about 100 nucleic acids and about 350 nucleic acids of a 
green-leaf tobacco nicotine demethylase sequence having a 
nucleic acid sequence of SEQ ID NO4 and a second poly 
nucleotide capable of forming a double stranded RNA With 
the ?rst. Also provided is a tobacco cell having a genome 
altered to inhibit the expression of at least a green-leaf nico 
tine demethylase, Where the cell is homozygous for a muta 
tion in the gene encoding the green-leaf nicotine demethy 
lase. Further provided is a tobacco cell comprising a 
trans gene containing green-leaf nicotine demethylase nucleic 
acid sequence that ?anks a selectable marker gene, Where the 
selectable marker gene disrupts the nicotine demethylase 
gene, thereby producing a tobacco cell Where the endogenous 
green-leaf nicotine demethylase gene has been disrupted. 
Alternatively provided is a tobacco cell comprising a trans 
gene containing green-leaf nicotine demethylase nucleic acid 
sequence that ?anks a selectable marker gene, Where the 
selectable marker gene disrupts the nicotine demethylase 
gene, thereby producing a tobacco cell Where the endogenous 
green-leaf nicotine demethylase gene has been disrupted. 
In a sixth aspect, the present invention is summarized as a 
method for reducing nornicotine levels in a plant part derived 
from a plant of the genus N icoliana, the method comprising a) 
inhibiting expression of a nicotine demethylase, Where the 
nicotine demethylase has an amino acid sequence set forth in 
the group consisting of SEQ ID NOs: 2 and 5-12; and b) 
reducing nornicotine levels in a plant part derived from a plant 
of the genus Nicoliana. Also provided is a method for reduc 
ing nomicotine levels in a tobacco product, the method com 
prising a) groWing a transgenic tobacco plant, Where the plant 
having a plant part that comprises an expression cassette 
comprising a heterologous promoter and a nicotine demethy 
lase, Where the nicotine demethylase has an amino acid 
sequence selected from the group consisting of SEQ ID 
NOs:2 and 5-12; and b) preparing a tobacco product from the 
tobacco plant part. Further provided is a method for reducing 
nomicotine levels in a tobacco product, the method compris 
ing a) groWing a transgenic tobacco plant, Where the plant has 
a plant part that comprises an antibody that speci?cally binds 
a polypeptide With an amino acid sequence selected from the 
group consisting of SEQ ID NOs:2 and 5-12; and b) preparing 
a tobacco product from the tobacco plant part. Alternatively 
provided is a method for reducing nomicotine levels in a 
tobacco product, the method comprising a) groWing a trans 
genic tobacco plant, Where the plant has a plant part that 
comprises a fragment of a green-leaf nicotine demethylase 
operably linked to a heterologous promoter and the fragment 
has at least 25 contiguous nucleic acids from a polynucleotide 
encoding a polypeptide selected from the group consisting of 
SEQ ID NOs:2 and 5-12; and b) preparing a tobacco product 
from the tobacco plant part. Also provided is a method for 
reducing nornicotine levels in a plant part derived from a plant 
of the genus Nicoliana, the method comprising a) modifying 












functional CYP82E5v2, Where the nonfunctional 
CYP82E5v2 has a substitution at an amino acid residue in a 
position selected from the group consisting of residues 235, 
449, 174, 410, 224, 72, 143 and 422, Where the numbering is 
according to SEQ ID NO:2; and b) reducing the level of 
nornicotine in a plant part derived from a plant of the genus 
Nicoliana. The present invention also provides a method for 
reducing the carcinogenic potential of a tobacco product, the 
method comprising preparing the tobacco product by a) 
groWing a transgenic tobacco plant, Where the plant com 
prises a plant part that comprises a fragment of a green-leaf 
nicotine demethylase operably linked to a heterologous pro 
moter and the fragment comprises at least 25 contiguous 
nucleic acids from a polynucleotide encoding a polypeptide 
selected from the group consisting of SEQ ID NOs:2 and 
5-12; and b) preparing a tobacco product from the tobacco 
plant part. Further, the present invention provides a method of 
reducing the conversion of nicotine to nornicotine in a Nic 
oliana plant comprising: a) transforming a Nicoliana plant 
With an nucleic acid construct comprising a promoter capable 
of functioning in a plant cell operably linked to a polynucle 
otide having a ?rst nucleic acid sequence comprising a region 
of betWeen 100 nucleic acids and about 350 nucleic acids of 
SEQ ID NO: 1, 3 or 4 and a second nucleic acid sequence 
capable of forming a double stranded RNA With the ?rst 
sequence; and b) regenerating a transgenic Nicoliana plant. 
In a seventh aspect, the present invention is summarized as 
a method of screening for a green-leaf nicotine demethylase 
sequence comprising a) obtaining a nucleic acid sequence 
that has at least 200 nucleic acids of sequence identity With 
SEQ ID NO: 1; and b) identifying a codon sequence encoding 
for a stop codon at position 422 of an encoded polypeptide, 
Where the numbering is according to SEQ ID N012. Also 
provided is a method of screening for green-leaf nicotine 
demethylase sequence comprising a) obtaining a nucleic acid 
sequence that has at least 200 nucleic acids of sequence 
identity With SEQ ID NO: 1; and b) identifying a codon 
sequence encoding for a codon that is not a proline at position 
449 of an encoded polypeptide, Where the numbering is 
according to SEQ ID N012. Further provided is a method for 
identifying a tobacco plant With loW levels of nornicotine, the 
method comprising a) obtaining a DNA sample from a 
tobacco plant of interest; and b) screening the sample for a 
mutation in SEQ ID NO: 1. The present invention also pro 
vides a method for reducing the level of nomicotine in a plant 
part derived from a plant of the genus Nicoliana, the method 
comprising a) inhibiting expression of a CYP82E4v2 nico 
tine demethylase and CYP82E5v2 nicotine demethylase; and 
b) reducing the level of nomicotine in a plant part derived 
from a plant of the genus Nicoliana. Also included is tobacco 
plant material comprising a polypeptide With an amino acid 
sequence of SEQ ID NO: 13 having a mutation at a position 
selected from the group consisting of residues 458, 364, 329 
and combinations thereof. Further included is tobacco plant 
material comprising a CYP82E4v2 having a mutation at a 
position selected from the group consisting of residues 458, 
364, 329 and combinations thereof, Where the numbering 
corresponds to SEQ ID NO: 13. Also included is tobacco 
plant material comprising a CYP82E4v2 having a mutation at 
residue 376, Where the residue is not valine and the number 
ing of residues corresponds to SEQ ID NO: 13. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1A-C shoW an amino acid sequence alignment of 
CYP82E2 gene family members that have been assayed for 
nicotine demethylase activity in yeast and/ or transgenic 
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plants. Sequences in italics and underlined are positive for 
nicotine demethylase activity (CYP82E4v2 and 
CYP82E5v2); sequences titled in black failed to show activ 
ity in an assay. Residues that differ among the members are 
shaded in grey. In FIG. 1, CYP82E4v2 is set forth in SEQ ID 
NO: 13; CYP82E4v6 is set forth in SEQ ID N0:26; 
CYP82E4v12 is set forth in SEQ ID N0:27; 58-166 is set 
forth in SEQ ID N0:28; CYP82E3 is set forth in SEQ ID 
N0:29; CYP82E2v1 is set forth in SEQ ID N0130; 
CYP82E2v2 is set forth in SEQ ID N031; and CYP82E5v2 
is set forth in SEQ ID N012. 
DESCRIPTION OF THE NUCLEIC ACID 
SEQUENCES 
SEQ ID NO: 1 sets forth a nucleic acid sequence of a 
coding region of CYP82E5v2. 
SEQ ID NO:2 sets forth an amino acid sequence of a 
CYP82E5v2. 
SEQ ID NO:3 sets forth a nucleic acid sequence of an 
intron of CYP82E5v2. 
SEQ ID NO:4 sets forth a nucleic acid sequence of a 
genomic CYP82E5v2. 
SEQ ID N0:5 sets forth an amino acid sequence 
CYP82E5v2 P235S. 
SEQ ID NO:6 sets forth an amino acid sequence 
CYP82E5v2 P449L. 
SEQ ID NO:7 sets forth an amino acid sequence 
CYP82E5v2 S174L. 
SEQ ID NO:8 sets forth an amino acid sequence 
CYP82E5v2 A410V. 
SEQ ID N029 sets forth an amino acid sequence 
CYP82E5v2 M2241. 
SEQ ID N0:10 sets forth an amino acid sequence 
CYP82E5v2 P72L. 
SEQ ID N0:11 sets forth an amino 
CYP82E5v2 L143F. 
SEQ ID N0:12 sets forth an amino 
CYP82E5v2 W422Stop. 
SEQ ID N0:13 sets forth an amino 
CYP82E4v2. 
SEQ ID N0:14 sets forth an amino 
CYP82E4v2 P458S. 
SEQ ID N0:15 sets forth an amino 
CYP82E4v2 K364N. 
SEQ ID N0:16 sets forth an amino 
CYP82E4v2 P38L. 
SEQ ID N0:17 sets forth an amino 
CYP82E4v2 E201K. 
SEQ ID NO: 18 sets forth an amino 
CYP82E4v2 R169Q. 
SEQ ID N0:19 sets forth an amino 
CYP82E4v2 G459R. 
SEQ ID N0:20 sets forth an amino 
CYP82E4v2 E296K. 
SEQ ID N0:21 sets forth an amino 
CYP82E4v2 T4271. 
SEQ ID N0:22 sets forth an amino 
CYP82E4v2 W329Stop. 
SEQ ID N0:23 sets forth an amino 
CYP82E4v2 V376M. 
SEQ ID N0:24 sets forth an amino 
CYP82E4v2 D171N. 
SEQ ID N0:25 sets forth an amino 
CYP82E4. 
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SEQ ID N0:27 sets forth an amino acid sequence 
CYP82E4v12. 
SEQ ID N0:28 sets forth an amino acid sequence 
58-166. 
SEQ ID N0:29 sets forth an amino acid sequence 
CYP82E3. 
SEQ ID N0130 sets forth an amino acid sequence 
CYP82E2v1. 
SEQ ID N0131 sets forth an amino acid sequence 
CYP82E2v2. 
SEQ ID N0z32 sets forth a nucleic acid sequence 
forWard primer for exon 1 of CYP82E4v2. 
SEQ ID N0z33 sets forth a nucleic acid sequence 
reverse primer for exon 1 of CYP82E4v2. 
SEQ ID N0z34 sets forth a nucleic acid sequence 
forWard primer for exon 2 of CYP82E4v2. 
SEQ ID N0z35 sets forth a nucleic acid sequence 
reverse primer for exon 2 of CYP82E4v2. 
SEQ ID N0:36 sets forth a nucleic acid sequence 
forWard primer for exon 1 of CYP82E5v2. 
SEQ ID N0z37 sets forth a nucleic acid sequence 
reverse primer for exon 1 of CYP82E5v2. 
SEQ ID N0z38 sets forth a nucleic acid sequence 
forWard primer for exon 2 of CYP82E5v2. 
SEQ ID N0z39 sets forth a nucleic acid sequence 
reverse primer for exon 2 of CYP82E5v2. 
SEQ ID N0:40 sets forth a nucleic acid sequence 
primer E5 Gen_F1. 
SEQ ID N0:41 
primer E5Gen_R1. 
SEQ ID N0:42 
primer E5Gen_F2. 
SEQ ID N0z43 
primer E5Gen_R2. 
SEQ ID N0:44 
primer E4Rt_F. 
SEQ ID N0:45 
primer E4Rt_R. 
SEQ ID N0:46 
primer E5Rt_F. 
SEQ ID N0:47 
primer E5Rt_R. 
SEQ ID N0:48 
primer G3PDH_F. 
SEQ ID N0:49 
primer G3PDH_R. 
SEQ ID N0:50 sets forth a nucleic acid sequence of a 
coding region of CYP82E4v2 and the encoded protein (i.e., 
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DEFINITIONS 
The present invention includes compositions and methods 
for inhibiting expression or function of nicotine demethylase 
polypeptides that are involved in the metabolic conversion of 
nicotine to nornicotine in a plant, particularly plants of the 
Nicoliana genus, including tobacco plants of various com 
mercial varieties. 
As used herein, “inhibit,” “inhibition” and “inhibiting” are 
de?ned as any method knoWn in the art or described herein, 
Which decreases the expression or function of a gene product 
of interest (i.e., the target gene product). 
“Inhibiting” can be in the context of a comparison betWeen 
tWo plants, for example, a genetically altered plant versus a 
Wild-type plant. The comparison can be betWeen plants, one 
of Which lacks a DNA sequence capable of reducing the 
agent. Inhibition of expression or function of a target gene 
US 8,124,851 B2 
product also can be in the context of a comparison between 
plant cells, organelles, organs, tissues orplant parts Within the 
same plant or betWeen different plants, and includes compari 
sons betWeen developmental or temporal stages Within the 
same plant or plant part or betWeen plants or plant parts. 
“Inhibiting” can include any relative decrement of function 
or production of a gene product of interest, up to and includ 
ing complete elimination of function or production of that 
gene product. When levels of an agent are compared, such a 
comparison is preferably carried out betWeen organisms With 
a similar genetic background. Preferably, a similar genetic 
background is a background Where the organisms being com 
pared share 50% or greater, more preferably 75% or greater, 
and, even more preferably 90% or greater sequence identity 
of nuclear genetic material. A similar genetic background is a 
background Where the organisms being compared are plants, 
and the plants are isogenic except for any genetic material 
originally introduced using plant transformation techniques 
or a mutation generated by human intervention. Measurement 
of the level or amount of an agent may be carried out by any 
suitable method, non-limiting examples of Which include, but 
are not limited to, comparison of mRNA transcript levels, 
protein or peptide levels, and/or phenotype, especially the 
conversion of nicotine to nornicotine. As used herein, mRNA 
transcripts can include processed and non-processed mRNA 
transcripts, and polypeptides or peptides can include 
polypeptides or peptides With or Without any post-transla 
tional modi?cation. 
As used herein, “host cell” means a cell that comprises a 
heterologous nucleic acid sequence of the invention. Though 
the nucleic acid sequences of the invention, and fragments 
and variants thereof, can be introduced into any cell of inter 
est, of particular interest are plant cells, more particularly 
cells of a Nicoliana plant species, for example, the tobacco 
plant species and varieties described herein beloW. 
As used herein, “variant” means a substantially similar 
sequence. A variant can have different function or a substan 
tially similar function as a Wild-type polypeptide of interest. 
For a nicotine demethylase, a substantially similar function is 
at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 75%, 60%, 
50%, 25% or 15% of Wild-type enZyme function of convert 
ing nicotine to nomicotine under the same conditions or in a 
near-isogenic line. A Wild-type CYP82E5v2 is SEQ ID N012. 
A Wild-type CYP82E4v2 is SEQ ID NO: 13. As used herein, 
a “variant polynucleotide” or “variant polypeptide” means a 
nucleic acid or amino acid sequence that is not Wild-type. 
A variant can have one addition, deletion or substitution; 
tWo or less additions, deletions or substitutions; three or less 
additions, deletions or substitutions; four or less additions, 
deletions or substitutions; or ?ve or less additions, deletions 
or substitutions. A mutation includes additions, deletions, and 
substitutions. Such deletions or additions can be at the C-ter 
minus, N-terminus or both the C- and N-termini. Fusion 
polypeptides or epitope-tagged polypeptides are also 
included in the present invention. “Silent” nucleotide muta 
tions do not change the encoded amino acid at a given posi 
tion. Amino acid substitutions can be conservative. A conser 
vative substitution is a change in the amino acid Where the 
change is to an amino acid Within the same family of amino 
acids as the original amino acid. The family is de?ned by the 
side chain of the individual amino acids. A family of amino 
acids can have basic, acidic, uncharged polar or nonpolar side 
chains. See, Alberts et al., (1994) Molecular biology ofthe 
cell (3rd ed., pages 56-57, Garland Publishing Inc., NeW 
York, N.Y.), incorporated herein by reference as if set forth in 
its entirety. A deletion, substitution or addition can be to the 












position. See, FIGS. 1A-C. As used herein, a “fragment” 
means a portion of a polynucleotide or a portion of a polypep 
tide and hence protein encoded thereby. 
As used herein, “plant part” means plant cells, plant pro 
toplasts, plant cell tissue cultures from Which a Whole plant 
can be regenerated, plant calli, plant clumps and plant cells 
that are intact in plants or parts of plants such as embryos, 
pollen, anthers, ovules, seeds, leaves, ?oWers, stems, 
branches, fruit, roots, root tips and the like. Progeny, variants 
and mutants of regenerated plants are also included Within the 
scope of the present invention, provided that they comprise 
the introduced polynucleotides of the invention. As used 
herein, “tobacco plant material” means any portion of a plant 
part or any combination of plant parts. 
As used herein, “operably linked” means a functional link 
age betWeen tWo or more elements. For example, an operable 
linkage betWeen a polynucleotide of interest and a regulatory 
sequence (i.e., a promoter) is a functional link that alloWs for 
expression of the polynucleotide of interest. Operably linked 
elements may be contiguous or non-contiguous. When used 
to refer to the fusing of tWo protein coding regions, by oper 
ably linked is intended that the coding regions are in the same 
reading frame. 
As used herein, “heterologous” means a sequence that 
originates from a foreign species, or, if from the same species, 
is substantially modi?ed from its native form in composition 
and/or genomic locus by deliberate human intervention. For 
example, a promoter operably linked to a heterologous poly 
nucleotide is from a species different from the species from 
Which the polynucleotide Was derived, or, if from the same/ 
analogous species, one or both are substantially modi?ed 
from their original form and/or genomic locus, or the pro 
moter is not the native promoter for the operably linked poly 
nucleotide. Furthermore, as used herein, “chimeric gene” 
means a coding sequence operably linked to a transcription 
initiation region that is heterologous to the coding sequence. 
DETAILED DESCRIPTION OF THE INVENTION 
Nicotine Demethylase Polynucleotides and Polypeptides, 
and Variants and Fragments Thereof 
Compositions of the present invention include cytochrome 
P450 polypeptides. Cytochrome P450 polypeptides can have 
nicotine demethylase activity. Such nicotine demethylase 
polynucleotides and polypeptides are involved in the meta 
bolic conversion of nicotine to nomicotine in plants, includ 
ing commercial varieties of tobacco plants. Also included are 
variants of such nicotine demethylases. In particular, compo 
sitions of the invention include isolated polypeptides com 
prising amino acid sequences as shoWn in SEQ ID NOS:2 and 
5-24, isolated polynucleotides comprising the nucleic acid 
sequences as shoWn in SEQ ID NOS:1, 3 and 4, and the 
isolated polynucleotides encoding polypeptides comprising 
amino acid sequences of SEQ ID NOS:2 and 5-24. The poly 
nucleotides of the present invention can ?nd use in inhibiting 
expression of nicotine demethylase polypeptides or variants 
thereof that are involved in the metabolic conversion of nico 
tine to nomicotine in plants, particularly tobacco plants. 
Some of the polynucleotides of the invention have mutations 
that inhibit nicotine demethylase activity of the Wild-type 
nicotine demethylase. The inhibition of polypeptides of the 
present invention is effective in loWering nomicotine levels in 
tobacco lines Where genetic conversion occurs in less than 
30%, 50%, 70% and 90% of the population, such as ?ue 
cured tobaccos. The inhibition of polypeptides of the present 
invention is effective in loWering nomicotine levels in 
tobacco populations Where genetic conversion occurs in at 
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least 90%, 80%, 70%, 60% and 50% of a plant population. A 
population preferably contains greater than about 25, 50, 100, 
500, 1,000, 5,000 or 25,000 plants Where, more preferably at 
least about 10%, 25%, 50%, 75%, 95% or 100% ofthe plants 
comprise a polypeptide of the present invention. 
The present invention further provides expression cassettes 
comprising all or a portion of the polynucleotides having a 
nucleic acid sequence set forth in SEQ ID NO: 1, 3 or 4, and 
the isolated polynucleotides encoding polypeptides having an 
amino acid sequence of SEQ ID NOS: 2 and 5-24, a comple 
ment or fragment thereof, or a sequence having substantial 
sequence identity to SEQ ID NO: 1, 3 or 4, or the polynucle 
otides encoding polypeptides having an amino acid sequence 
of SEQ ID NOS:2 and 5-24, or a complement or fragment 
thereof, operably linked to a heterologous promoter that is 
functional in a plant cell for use in expressing an inhibitory 
RNA transcript that interferes With expression (i.e., transcrip 
tion and/ or translation) of nicotine demethylase polypeptides. 
In some embodiments, the expression cassettes comprise the 
nucleotide sequence as shoWn in SEQ ID NO: 1, 3 or 4, a 
complement or fragment thereof, or a sequence having sub 
stantial sequence identity to SEQ ID NO: 1, 3 or 4, or a 
complement or fragment thereof. Introduction of these 
expression cassettes into a Nicoliana plant of interest; par 
ticularly a tobacco plant of varieties commonly knoWn as ?ue 
or bright varieties, Burley varieties, dark varieties and orien 
tal/Turkish varieties, results in the production of tobacco 
plants having reduced amounts of nornicotine and NNN. Leaf 
and stem material from these transgenic plants can be used to 
produce a variety of tobacco products having, reduced levels 
of nornicotine, and a concomitant reduction NNN. 
The nicotine demethylase polynucleotides and encoded 
polypeptides of the present invention include a novel cyto 
chrome P450 gene, designated the CYP82E5v2 nicotine 
demethylase gene, that is neWly identi?ed as having a role in 
the metabolic conversion of nicotine to nornicotine in tobacco 
plants. Suppression of the expression of the encoded polypep 
tide in transgenic tobacco plants results in a signi?cant reduc 
tion in the accumulation of nornicotine in the green leaves of 
these transgenic plants. While not being bound by theory, the 
metabolic role of these polypeptides may be a direct one, i.e., 
directly catalyZing the N-demethylation reaction, or an indi 
rect one, i.e., in the form of production of a product that leads 
to the up-regulation of the nicotine demethylase activity of 
the leaf. Regardless of the mechanism, any means by Which 
expression and/or function of the polypeptides of the present 
invention are targeted for inhibition or site-directed mutagen 
esis Within a Nicoliana plant Will be effective in reducing 
nornicotine levels, and levels of NNN, Within leaves and 
stems of these plants. 
The invention encompasses isolated or substantially puri 
?ed polynucleotide or polypeptide compositions of the 
present invention. An “isolated” or “puri?ed” polynucleotide 
or polypeptide, or biologically active portion thereof, is sub 
stantially or essentially free from components that normally 
accompany or interact With the polynucleotide or protein as 
found in its naturally occurring environment. Thus, an iso 
lated or puri?ed polynucleotide or polypeptide is substan 
tially free of other cellular material or culture medium When 
produced by recombinant techniques, or substantially free of 
chemical precursors or other chemicals When chemically syn 
thesiZed. Optimally, an “isolated” polynucleotide is free of 
sequences (optimally protein encoding sequences) 110 that 
naturally ?ank the polynucleotide (i.e., sequences located at 
the 5' and 3' ends of the polynucleotide) in the genomic DNA 
of the organism from Which the polynucleotide is derived. For 












otide can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 
0.5 kb or 0.1 kb of nucleotide sequence that naturally ?ank the 
polynucleotide in genomic DNA of the cell from Which the 
polynucleotide is derived. A polypeptide that is substantially 
free of cellular material includes preparations having less 
than about 30%, 20%, 10%, 5% or 1% (by dry Weight) of 
contaminating protein. When the polypeptide of the invention 
or biologically active portion thereof is recombinantly pro 
duced, optimally culture medium represents less than about 
30% 20%, 10%, 5% or 1% (by dry Weight) of chemical 
precursors or non-protein-of-interest chemicals. 
Fragments of the disclosed polynucleotides and polypep 
tides encoded thereby are also encompassed by the present 
invention. Fragments of a polynucleotide may encode 
polypeptide fragments that retain the biological activity of the 
native polypeptide and hence are involved in the metabolic 
conversion of nicotine to nornicotine in a plant. Alternatively, 
fragments of a polynucleotide that are useful as hybridization 
probes or PCR primers using methods described beloW gen 
erally do not encode fragment polypeptides retaining biologi 
cal activity. Furthermore, fragments of the disclosed poly 
nucleotides include those that can be assembled Within 
recombinant constructs for use in gene silencing With any 
method knoWn in the art, including, but not limited to, sense 
suppression/cosuppression, antisense suppression, double 
stranded RNA (dsRNA) interference, hairpin RNA interfer 
ence and intron-containing hairpin RNA interference, ampli 
con-mediated interference, riboZymes and small interfering 
RNA or micro RNA, as described in the art and herein beloW. 
Thus, fragments of a polynucleotide may range from at least 
about 20 nucleotides, about 50 nucleotides, about 70 nucle 
otides, about 100 nucleotides about 150 nucleotides, about 
200 nucleotides, 250 nucleotides, 300 nucleotides and up to 
the full-length polynucleotide encoding the polypeptides of 
the invention, depending upon the desired outcome. For 
example, the fragments of a polynucleotide can be betWeen 
100 and about 350 nucleotides, betWeen 100 and about 325 
nucleotides, betWeen 100 and about 300 nucleotides, betWeen 
about 125 and about 300 nucleotides, betWeen about 125 and 
about 275 nucleotides in length, betWeen about 200 to about 
320 contiguous nucleotides, betWeen about 200 and about 
420 contiguous nucleotides in length betWeen about 250 and 
about 450 contiguous nucleotides in length. Alternatively, the 
fragment can be betWeen about 300 and about 450 contiguous 
nucleotides in length. 
A fragment of a nicotine demethylase polynucleotide of 
the present invention that encodes a biologically active por 
tion of a cytochrome P450 polypeptide of the present inven 
tion Will encode at least 15, 25, 30, 50, 75, 100, 125, 150, 175, 
200, 250, 300, 350, 400, 450 or 500 contiguous amino acids, 
or up to the total number of amino acids present in a full 
length nicotine demethylase polypeptide of the invention 
(e.g., 517 amino acids for SEQ ID NOS:2 and 5), or Will 
encode at least 15, 25, 30, 50, 75, 100, 125, 150 or up to the 
total number of amino acids present in a partial-length cyto 
chrome P450 polypeptide of the invention (e.g., 422 for SEQ 
ID NO: 12). Preferably, the fragment comprises up to amino 
acid residue 330 of the encoded polypeptide. A biologically 
active portion of a nicotine demethylase polypeptide can be 
prepared by isolating a portion of one of the cytochrome P450 
polynucleotides of the present invention, expressing the 
encodedportion of the cytochrome P450 polypeptide (e. g., by 
recombinant expression in vitro), and assessing the activity of 
the encoded portion of the cytochrome P450 polypeptide, i.e., 
the ability to promote conversion of nicotine to nornicotine, 
using assays knoWn in the art and those provided herein 
beloW. 
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Polynucleotides that are fragments of a cytochrome P450 
nucleotide sequence of the present invention comprise at least 
16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 
550, 600, 650, 700, 800, 900, 950, 1000, 1050, 1100, 1150, 
1200, 1250, 1300,1350, 1400,1450, 1500,1550, 1600,1650 
or 1700 contiguous nucleic acids, or up to the number of 
nucleotides present in a full-length cytochrome P450 poly 
nucleotide as disclosed herein (e.g., 1554 for SEQ ID NO:1; 
or 2608 for SEQ ID NO:4). Polynucleotides that are frag 
ments of a cytochrome P450 nucleotide sequence of the 
present invention comprise fragments from about 20 to about 
1700 contiguous nucleic acids, from about 50 to about 1600 
contiguous nucleic acids, from about 75 to about 1500 con 
tiguous nucleic acids, from about 100 to about 1400 nucleic 
acids, from about 150 to about 1300 contiguous nucleic acids, 
from about 150 to about 1200 contiguous nucleic acids, from 
about 175 to about 1 100 contiguous nucleic acids, from about 
200 to about 1000 contiguous nucleic acids, from about 225 
to about 900 contiguous nucleic acids, from about 500 to 
about 1600 contiguous nucleic acids, from about 775 to about 
1700 contiguous nucleic acids, from about 1000 to about 
1700 contiguous nucleic acids, or from about 300 to about 
800 contiguous nucleic acids from a cytochrome P450 poly 
nucleotide as disclosed herein. For example, polynucleotide 
fragment can comprise a polynucleotide sequence containing 
the nucleic acid sequence from the polynucleotide at about 
position 700 to about position 1250 of a cytochrome P450 
coding sequence, at about position 700 to about position 1250 
of a cytochrome P450 genomic sequence, at about position 10 
to about position 900 of a cytochrome P450 intron sequence, 
or at about position 100 to about position 800 of a cytochrome 
P450 intron sequence. 
Variants of the disclosed polynucleotides and polypeptides 
encoded thereby are also encompassed by the present inven 
tion. Naturally occurring variants include those variants that 
share substantial sequence identity to the disclosed cyto 
chrome P450 polynucleotides and polypeptides disclosed 
herein. Naturally occurring variants can share substantial 
functional identity to the disclosed cytochrome P450 poly 
nucleotides disclosed herein. The compositions and methods 
of the invention can be used to target expression or function of 
any naturally occurring cytochrome P450 that shares sub stan 
tial sequence identity to the disclosed cytochrome P450 
polypeptides. Such cytochrome P450 can possess the relevant 
cytochrome P450 activity, i.e., involvement in the metabolic 
conversion of nicotine to nornicotine in plants, or not. Such 
variants may result from, e.g., genetic polymorphism or from 
human manipulation as occurs With breeding and selection. 
Biologically active variants of a cytochrome P450 protein of 
the invention, such as variants of the polypeptide set forth in 
SEQ ID NO2 and 5-24, Will have at least about 40%, 45%, 
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more 
sequence identity to the amino acid sequence for the Wild 
type protein as determined by sequence alignment programs 
and parameters described elseWhere herein, and can be char 
acteriZed by a functional involvement in the metabolic con 
version of nicotine to nornicotine in plants or lack thereof. A 
biologically active variant of a polypeptide of the invention 
may differ by as feW as 1-15 amino acid residues, as feW as 10, 
as feW as 9, as feW as 8, as feW as 7, as feW as 6, as feW as 5, 
as feW as 4, as feW as 3, as feW as 2, or as feW as 1 amino acid 
residue from the Wild-type polypeptide. A biologically inac 
tive variant of a protein of the invention may differ from that 












10, as feW as 9, as feW as 8, as feW as 7, as feW as 6, as feW as 
5, as feW as 4, as feW as 3, as feW as 2, or as feW as 1 amino acid 
residue. 
Variants of the polynucleotides of the present invention 
include those naturally occurring polynucleotides that encode 
a nicotine demethylase polypeptide that is involved in the 
metabolic conversion of nicotine to nornicotine in plants. 
Such polynucleotide variants can comprise a deletion and/or 
addition of one or more nucleotides at one or more sites 
Within the native polynucleotide disclosed herein and/or a 
substitution of one or more nucleotides at one or more sites in 
the native polynucleotide. Because of the degeneracy of the 
genetic code, conservative variants for polynucleotides 
include those sequences that encode the amino acid sequence 
of one of the cytochrome P450 polypeptides of the invention. 
Naturally occurring variants such as these can be identi?ed 
With the use of Well-known molecular biology techniques, as, 
e.g., With polymerase chain reaction (PCR) and hybridization 
techniques as are knoWn in the art and disclosed herein. 
Variant polynucleotides also include synthetically derived 
polynucleotides, such as those generated, e.g., by using site 
directed mutagenesis but Which still share substantial 
sequence identity to the naturally occurring sequences dis 
closed herein, and thus can be used in the methods of the 
invention to inhibit the expression or function of a nicotine 
demethylase that is involved in the metabolic conversion of 
nicotine to nornicotine, including the nicotine demethylase 
polypeptides set forth in SEQ ID NOS:2, 5, 7-11, 13, 16-21 
and 23-24. Generally, variants of a particular polynucleotide 
of the invention, e.g., the polynucleotide sequence of SEQ ID 
N023 or the polynucleotide sequence encoding the amino 
acid sequence set forth in SEQ ID NO2 and 5-24, Will have 
at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 
80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 
98%, 99% or more sequence identity to that particular poly 
nucleotide as determined by sequence alignment programs 
and parameters described elseWhere herein. 
Variants of a particularpolynucleotide of the present inven 
tion (also referred to as the reference polynucleotide) can also 
be evaluated by comparison of the percent sequence identity 
betWeen the polypeptide encoded by the reference polynucle 
otide and the polypeptide encoded by a variant polynucle 
otide. Percent sequence identity betWeen any tWo polypep 
tides can be calculated using sequence alignment programs 
and parameters described elseWhere herein. Where any given 
pair of polynucleotides of the invention is evaluated by com 
parison of the percent sequence identity shared by the tWo 
polypeptides they encode, the percent sequence identity 
betWeen the tWo encoded polypeptides is at least about 40%, 
45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more 
sequence identity. A variant polypeptide of the present inven 
tion can include a polypeptide having a serine at position 458, 
an asparagine at position 364 of the cytochrome P450 
polypeptide, a stop codon at position 329 of the cytochrome 
P450 or any combination thereof, Where the numbering cor 
responds to SEQ ID NO:13. 
Furthermore, the polynucleotides of the invention can be 
used to isolate corresponding cytochrome P450 sequences 
from other organisms, particularly other plants, more particu 
larly other members of the Nicoliana genus. PCR, hybridiza 
tion and other like methods can be used to identify such 
sequences based on their sequence homology to the 
sequences set forth herein. Sequences isolated based on their 
sequence identity to the nucleotide sequences set forth herein 
or to variants and fragments thereof are encompassed by the 
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present invention. Such sequences include sequences that are 
orthologs of the disclosed sequences. 
As used herein, “orthologs” means genes derived from a 
common ancestral gene that are found in different species as 
a result of speciation. Genes found in different species are 
considered orthologs When their nucleotide sequences and/or 
their encoded protein sequences share at least 60%, 70%, 
75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 
97%, 98%, 99% or greater sequence identity. Functions of 
orthologs are often highly conserved among species. Thus, 
isolated polynucleotides that encode for a nicotine demethy 
lase polypeptide that is involved in the nicotine-to-nomico 
tine metabolic conversion and Which hybridize under strin 
gent conditions to the cytochrome P450 sequences disclosed 
herein, or to variants or fragments thereof, are encompassed 
by the present invention. Such sequences can be used in the 
methods of the present invention to inhibit expression of 
nicotine demethylase polypeptides that are involved in the 
metabolic conversion of nicotine to nomicotine in plants. 
Using PCR, oligonucleotide primers can be designed for 
use in PCR reactions to amplify corresponding DNA 
sequences from cDNA or genomic DNA extracted from any 
plant of interest. Methods for designing PCR primers and 
PCR cloning are generally knoWn in the art and are disclosed 
in Sambrook et al. (1989) Molecular cloning: a laboratory 
manual (2d ed, Cold Spring Harbor Laboratory Press, Plain 
vieW, N.Y.). lnnis et al., eds. (1990) PCRprotocols: a guide to 
methods and applications (Academic Press, NeWYork); Innis 
& Gelfand, eds. (1995) PCR strategies (Academic Press, 
NeW York); and Innis & Gelfand, eds. (1999) PCR methods 
manual (Academic Press, NeW York). Known methods of 
PCR include, but are not limited to, methods using paired 
primers, nested primers, single speci?c primers, degenerate 
primers, gene-speci?c primers, vector-speci?c primers, par 
tially mismatched primers and the like. 
Hybridization techniques involve the use of all or part of a 
knoWn polynucleotide as a probe that selectively hybridizes 
to other corresponding polynucleotides present in a popula 
tion of cloned genomic DNA fragments or cDNA fragments 
(i.e., genomic or cDNA libraries) from a chosen organism. 
Hybridization may be carried out under stringent condi 
tions. As used herein, “stringent conditions” or “stringent 
hybridization conditions” means conditions under Which a 
probe Will hybridize to its target sequence to a detectably 
greater degree than to other sequences (e.g., at least tWo-fold 
over background). Stringent conditions are sequence-depen 
dent and Will be different in different circumstances. By con 
trolling the stringency of the hybridization and/or Washing 
conditions, target sequences that are 100% complementary to 
the probe can be identi?ed (homologous probing). Alterna 
tively, stringency conditions can be adjusted to alloW some 
mismatching in sequences so that loWer degrees of similarity 
are detected (heterologous probing). Generally, a probe is less 
than about 1000 nucleic acids in length, optimally less than 
500 nucleic acids in length. 
Typically, stringent conditions Will be those in Which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 
7.0 to 8.3 and the temperature is at least about 30° C. Stringent 
conditions may also be achieved With the addition of desta 
bilizing agents such as formamide. Exemplary loW stringency 
conditions include hybridization With a buffer solution of 30 
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl 
sulphate) at 37° C., and a Wash in 1x to 2><SSC (20><SSC:3.0 
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary 
moderate stringency conditions include hybridization in 40 to 












in 0.5>< to 1><SSC at 55 to 60° C. Exemplary high stringency 
conditions include hybridization in 50% formamide, 1 M 
NaCl, 1% SDS at 37° C. and a Wash in 0.1><SSC at 60 to 65° 
C. Optionally, Wash buffers may comprise about 0.1% to 
about 1% SDS. Duration of hybridization is generally less 
than about 24 hours, usually about 4 to about 12 hours. The 
duration of the Wash time Will be at least a length of time 
suf?cient to reach equilibrium. 
Preferably, stringency conditions include hybridization in 
a solution containing 5><SSC, 0.5% SDS, 5><Denhardt’s, 0.45 
ug/ul poly A RNA, 0.45 ug/ul calf thymus DNA and 50% 
formamide at 42° C., and at least one post-hybridization Wash 
in a solution comprising from about 0.01><SSC to about 
1><SSC. The duration of hybridization is from about 14 to 
about 16 hours. 
Speci?city is typically the function of post-hybridization 
Washes, the critical factors being the ionic strength and tem 
perature of the ?nal Wash solution. For DNA-DNA hybrids, 
the Tm can be approximated from the equation of Meinkoth & 
Wahl (1984)Anal. Biochem. 138:267-284: Tm:81.5° C.+16.6 
(log M)+0.41 (% GC)-0.61 (% form)-500/L; Where M is the 
molarity of monovalent cations, % GC is the percentage of 
guanosine and cytosine nucleotides in the DNA, % form is the 
percentage of formamide in the hybridization solution, and L 
is the length of the hybrid in base pairs. The Tm is the tem 
perature (under de?ned ionic strength and pH) at Which 50% 
of a complementary target sequence hybridizes to a perfectly 
matched probe. Tm is reduced by about 1° C. for each 1% of 
mismatching; thus, Tm, hybridization, and/ or Wash condi 
tions can be adjusted to hybridize to sequences of the desired 
identity. For example, if sequences With 290% identity are 
sought, the Tm can be decreased 10° C. Generally, stringent 
conditions are selected to be about 5° C. loWer than the 
thermal melting point (Tm) for the speci?c sequence and its 
complement at a de?ned ionic strength and pH. HoWever; 
severely stringent conditions can utilize a hybridization and/ 
or Wash at 1, 2, 3 or 4° C. loWer than the thermal melting point 
(Tm); moderately stringent conditions can utilize a hybridiza 
tion and/ or Wash at 6, 7, 8, 9 or 10° C. loWer than the thermal 
melting point (Tm); loW stringency conditions can utilize a 
hybridization and/or Wash at 11, 12, 13, 14, 15 or 20° C. loWer 
than the thermal melting point (Tm). Using the equation, 
hybridization and Wash compositions, and desired Tm, those 
of ordinary skill Will understand that variations in the strin 
gency of hybridization and/or Wash solutions are inherently 
described. If the desired degree of mismatching results in a 
Tm, of less than 45° C. (aqueous solution) or 32° C. (forma 
mide solution), it is optimal to increase the SSC concentration 
so that a higher temperature can be used. An extensive guide 
to the hybridization of nucleic acids is found in Tijssen(1993) 
Laboratory techniques in biochemistry and molecular biol 
ogy-hybridization with nucleic acid probes, Part 1, Chapter 2 
(Elsevier, NY); and Ausubel et al., eds. (1995) Current pro 
tocols in molecular biology, Chapter 2 (Greene Publishing 
and Wiley-lnterscience, NeWYork). See also, Sambrook et al. 
(1 989) Molecular cloning: a laboratory manual (2d ed., Cold 
Spring Harbor Laboratory Press, PlainvieW, N.Y.). 
Hybridization probes may be genomic DNA fragments, 
cDNA fragments, RNA fragments or other oligonucleotides, 
and may be labeled With a detectable group such as 32P, or any 
other delectable marker. For example, probes for hybridiza 
tion can be made by labeling synthetic oligonucleotides based 
on the cytochrome P450 polynucleotides sequences of the 
present invention. Methods for preparation of probes for 
hybridization and for construction of cDNA and genomic 
libraries are generally knoWn in the art and are disclosed in 
Sambrook et al., supra. 
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For example, the cytochrome P430 polynucleotides dis 
closed herein, or one or more portions thereof, may be used as 
probes capable of speci?cally hybridizing to corresponding 
cytochrome P450 polynucleotides and messenger RNAs. To 
achieve speci?c hybridization under a variety of conditions, 
such probes include sequences that are unique among cyto 
chrome P450 polynucleotide sequences or unique to one of 
the cytochrome P450 polynucleotide sequences, including 
upstream regions 5' to the coding sequence and doWnstream 
regions 3' to the coding sequence and an intron region, and are 
optimally at least about 10 contiguous nucleotides in length, 
more optimally at least about 20 contiguous nucleic acids in 
length, more optimally at least about 50 contiguous nucleic 
acids in length, more optimally at least about 75 contiguous 
nucleic acids in length, and more optimally at least about 100 
contiguous nucleic acids in length. Such probes may be used 
to amplify corresponding cytochrome P450 polynucleotides. 
This technique may be used to isolate additional coding 
sequences or mutations from a desired plant or as a diagnostic 
assay to determine the presence of coding sequences in a 
plant. Hybridization techniques include hybridization screen 
ing of plated DNA libraries (either plaques or colonies; see, 
e.g., Sambrook et al., supra. 
As used herein, With respect to the sequence relationships 
betWeen tWo or more polynucleotides or polypeptides, the 
term “reference sequence” means a de?ned sequence used as 
a basis for sequence comparison. A reference sequence may 
be a subset or the entirety of a speci?ed sequence; for 
example, as a segment of a full-length cDNA or gene 
sequence, or the complete cDNA or gene sequence. 
As used herein, “comparison WindoW” means a contiguous 
and speci?ed segment of a polynucleotide sequence, Where 
the polynucleotide sequence in the comparison WindoW may 
comprise additions or deletions (i.e., gaps) compared to the 
reference sequence (Which does not comprise additions or 
deletions) for optimal alignment of the tWo polynucleotides. 
Generally, a comparison WindoW is at least 20 contiguous 
nucleic acids in length, and optionally can be 30, 40, 50 or 100 
contiguous nucleic acids or longer. Those of skill in the art 
understand that to avoid a high similarity to a reference 
sequence due to inclusion of gaps in the polynucleotide 
sequence a gap penalty is typically introduced and is sub 
tracted from the number of matches. 
Methods of alignment of sequences for comparison are 
Well knoWn in the art. Thus, the determination of percent 
sequence identity betWeen any tWo sequences can be accom 
plished using a mathematical algorithm. Non-limiting 
examples of such mathematical algorithms are the algorithm 
of Myers & Miller (1988) CABIOS 4: 11-17; the local align 
ment algorithm ofSmith et al. (1981)Adv. Appl. Math. 2:482; 
the global alignment algorithm of Needleman & Wunsch 
(1970) J. Mol. Biol. 48:443-453; the search-for-local align 
ment method of Pearson & Lipman (1988) Proc. Natl. Acad. 
Sci. 85 :2444-2448; the algorithm of Karlin &Altschul (1990) 
Proc. Natl. Acad. Sci. USA 872264, modi?ed as in Karlin & 
Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. 
The BLAST programs of Altschul et al. (1 990) J. Mol. Biol. 
215:403 are based on the algorithm of Karlin & Altschul 
(1990) supra. BLAST nucleotide searches can be performed 
With the BLASTN program, score:100, Wordlength:12, to 
obtain nucleotide sequences homologous to a nucleotide 
sequence encoding a protein of the invention. BLAST protein 
searches can be performed With the BLASTX program, 
score:50. Wordlength:3, to obtain amino acid sequences 
homologous to a protein or polypeptide of the invention. To 
obtain gapped alignments for comparison purposes, Gapped 












chul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, 
PSI-BLAST (in BLAST 2.0) can be used to perform an iter 
ated search that detects distant relationships betWeen mol 
ecules. See Altschul et al. (1997) supra. When utilizing 
BLAST, Gapped BLAST, PSI-BLAST, the default param 
eters of the respective programs (e.g., BLASTN for nucle 
otide sequences, BLASTX for proteins) can be used (See 
WWW.ncbi.nlna.nih.gov). Alignment may also be performed 
manually by inspection. 
The sequence identity/similarity values provided herein 
Were calculated using the BLASTX (Altschul et al. (1997) 
supra), Clustal W (Higgins et al. (1994) Nucleic Acids Res. 
22:4673-4680), and GAP (University of Wisconsin Genetic 
Computing Group softWare package) algorithms using 
default parameters. The present invention also encompasses 
the use of any equivalent program thereof for the analysis and 
comparison of nucleic acid and protein sequences. By 
“equivalent program” is intended any sequence comparison 
program that, for any tWo sequences in question, generates an 
alignment having identical nucleotide or amino acid residue 
matches and an identical percent sequence identity When 
compared to the corresponding alignment generated by 
BLASTX. Clustal W, or GAP. 
For purposes of the foregoing discussion of variant nucle 
otide and polypeptide sequences encompassed by the present 
invention, “sequence identity” or “identity” in the context of 
tWo polynucleotides or polypeptide sequences makes refer 
ence to the residues in the tWo sequences that are the same 
When aligned for maximum correspondence over a speci?ed 
comparison WindoW. When percentage of sequence identity 
is used in reference to proteins it is recognized that residue 
positions Which are not identical often differ by conservative 
amino acid substitutions, Where amino acid residues are sub 
stituted for other amino acid residues With similar chemical 
properties (e.g., charge or hydrophobicity) and therefore do 
not change the functional properties of the molecule. When 
sequences differ in conservative substitutions, the percent 
sequence identity may be adjusted upWards to correct for the 
conservative nature of the substitution. Sequences that differ 
by such conservative substitutions are said to have “sequence 
similarity” or “similarity.” Means for malting this adjustment 
are Well knoWn to those of skill in the art. Typically this 
involves scoring a conservative substitution as a partial rather 
than a full mismatch, thereby increasing the percentage 
sequence identity. Thus, for example, Where an identical 
amino acid is given a score of 1 and a non-conservative 
substitution is given a score of zero, a conservative substitu 
tion is given a score betWeen zero and 1. The scoring of 
conservative substitutions is calculated, e. g., as implemented 
in the program PC/GENE (lntelligenetics; Mountain VieW, 
Calif.). 
As used herein, “percentage of sequence identity” means 
the value determined by comparing tWo optimally aligned 
sequences over a comparison WindoW, Where the portion of 
the polynucleotide sequence in the comparison WindoW may 
comprise additions or deletions (i.e., gaps) as compared to the 
reference sequence (Which does not comprise additions or 
deletions) for optimal alignment of the tWo sequences. The 
percentage is calculated by determining the number of posi 
tions at Which the identical nucleic acid base or amino acid 
residue occurs in both sequences to yield the number of 
matched positions, dividing the number of matched positions 
by the total number of positions in the WindoW of comparison, 
and multiplying the result by 100 to yield the percentage of 
sequence identity. 
Thus, cytochrome P450 polynucleotide and polypeptide 
sequences can be identi?ed using the sequences provided 
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herein. Such methods include obtaining a polynucleotide or 
polypeptide sequence at least 80%, 85%, 90%, 95%, 98% or 
99% sequence identity With the polynucleotide sequence of 
SEQ ID NO: 1, 3 or 4 or a complement or fragment thereof, or 
a polypeptide sequence of SEQ ID NO12 or 5-24. A preferred 
embodiment includes a polypeptide corresponding to SEQ ID 
NO113 that has a serine at position 458 or an asparagine at 
position 364 of the cytochrome P450 polypeptide, or a stop 
codon at position 329 of the cytochrome P450, or a combi 
nation thereof, Where the numbering corresponds to SEQ ID 
NO: 13. 
Expression Cassettes for Use in the Methods of Invention 
Compositions of the present invention further include 
expression cassettes comprising inhibitory sequences 
capable of inhibiting expression or function of a nicotine 
demethylase polypeptide involved in the conversion of nico 
tine to nomicotine in a Nicotiana plant or plant part thereof, 
Where the inhibitory sequences are operably linked to a pro 
moter that is functional in a plant cell. In this manner, expres 
sion cassettes comprising all or part of the sequence set forth 
in SEQ ID NO11, 3 or 4 or encoding SEQ ID NO12 or 5-24, a 
complement or fragment thereof, or sequences sharing sub 
stantial sequence identity to such sequences, or a complement 
or fragment thereof, operably linked to a promoter that is 
functional in a plant cell are constructed for use in the gene 
silencing methods of the present invention described herein 
beloW. Such sequences are referred to herein as “inhibitory 
sequences” or “inhibitory polynucleotide sequences,” as they 
are capable of being expressed as an RNA molecule that 
inhibits expression (i.e., transcription and/or translation) of 
the target cytochrome P450 polypeptide, for example, the 
polypeptide set forth in SEQ ID NO12 or 5-24 and variants 
thereof, Where the variant polypeptides have substantial 
sequence identity to these disclosed cytochrome P450 
polypeptides. Such variants may or may not be involved in the 
metabolic conversion of nicotine to nornicotine in a plant. 
Such sequences also include fragment sequences of the target 
cytochrome P450 polynucleotide or polypeptide. For 
example, a fragment sequence can include any portion of the 
cytochrome P450 sequence, including coding and non-cod 
ing sequence (e.g., 5' UTR, intron, and 3' UTR sequences), 
and can include fragments betWeen 100 and about 350 
nucleic acids, betWeen about 125 and about 300 nucleic acids, 
orbetWeen about 125 and about 275 nucleic acids. Preferably, 
a fragment of nicotine demethylase can be betWeen about 20 
and about 420, about 30 and about 420, betWeen about 40 and 
about 320, betWeen about 50 and about 200, betWeen about 50 
and about 400, betWeen about 50 and about 420, betWeen 
about 60 and about 320, about 70 and about 220, betWeen 
about 100 and about 200, betWeen about 100 and about 320, 
betWeen about 150 and about 200, betWeen about 150 and 
about 220, betWeen about 150 and about 400, betWeen about 
200 and about 300, or betWeen about 300 and about 400 
contiguous nucleic acids. Alternatively, a fragment of a cyto 
chrome P450 can be about 100, about 150, about 200, about 
220, about 250, about 300, about 320, or about 350 contigu 
ous nucleic acids in length. Alternatively yet, a cytochrome 
P450 fragment can be reduced in length by about 20, about 
40, about 60, about 80, about 100, about 120, about 140, about 
160, about 180, about 200, about 220, about 240, about 260, 
about 280, about 290, about 300, about 320, about 340, about 
360, about 380, about 400 contiguous nucleic acids compared 
to the full-length. For all of these cytochrome P450 frag 
ments, the truncation or deletion can start at the 5' end, start at 












chrome P450 intron. For a cytochrome P450 intron fragment, 
the entire sequence of a cytochrome P450 intron can be SEQ 
ID NO13. 
Furthermore, a fragment of a cytochrome P450 polynucle 
otide or polypeptide can contain contiguous nucleotides from 
about 1, 2, 5, 10, 20, 30, 40, 50, 60,70, 80, or 90% ofthe entire 
gene. Alternatively stated, a fragment of a cytochrome P450 
polynucleotide or polypeptide can be betWeen about 
5%-about 80%, betWeen about 10%-about 70%, betWeen 
about 10%-about 60%, betWeen about 10%-about 50%, 
betWeen about 25%-about 60%, betWeen about 25%-about 
50%, betWeen about 40%-about 60%, betWeen about 40% 
about 80%, betWeen about 50%-about 90% of the length of an 
entire cytochrome P450. 
Expression cassettes of the present invention include those 
that encompass additional domains that modulate the level of 
expression, the developmental timing of expression, or tissue 
type that expression occurs in (e.g., AU Patent No. AU-A 
77751/94 and US. Pat. Nos. 5,466,785 and 5,635,618). Pro 
moters can be selected based on the desired outcome. The 
nucleic acids of the present invention can be combined With 
inducible, constitutive, pathogen- or Wound-induced, envi 
ronmentally- or developmentally-regulated, cell- or tissue 
preferred promoter, or other promoters for expression in 
plants. 
Chemical-inducible promoters can be used to inhibit the 
expression of a cytochrome P450 that is involved in the meta 
bolic conversion of nicotine to nomicotine in a plant through 
the application of an exogenous chemical regulator. Chemi 
cal-inducible promoters are knoWn in the art and include, but 
are not limited to, the tobacco PR-la promoter, Which is 
activated by salicylic acid. Other chemical-inducible promot 
ers of interest include steroid-responsive promoters (see, e. g., 
the glucocorticoid-inducible promoter (Schena et al. (1991) 
Proc. Natl. Acad. Sci. USA 88: 10421-10425; and McNellis et 
al. (1998) Plant J. 14(2):247-257) and tetracycline-inducible 
promoters (see, e.g., GatZ et al. (1991) Mol. Gen. Genet. 
2271229-237; and US. Pat. Nos. 5,814,618 and 5,789,156), 
each of Which is incorporated herein by reference as if set 
forth in its entirety. 
Constitutive promoters include, e.g., the core promoter of 
the Rsyn7 promoter and outer constitutive promoters dis 
closed in US. Pat. No. 6,072,050; the core CaMV 35S pro 
moter (Odell et al. (1985) Nature 3131810-812); ubiquitin 
(Christensen et al. (1989) Plant Mol. Biol. 121619-632; and 
Christensen et al. (1992) Plant Mol. Biol. 181675-689); 
pEMU (Last et al. (1991) Theo}: Appl. Genet. 811581-588); 
MAS (Velten et al. (1984) EMBO J 312723-2730); ALS 
promoter (US. Pat. No. 5,659,026), and the like. Other con 
stitutive promoters include, e.g., those disclosed in US. Pat. 
Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 
5,399,680; 5,268,463; 5,608,142 and 6,177,611. 
Tissue-preferred promoters can be utiliZed to target expres 
sion of an inhibitory polynucleotide sequence of the present 
invention Within a particular plant tissue. Tissue-preferred 
promoters include those disclosed inYamamoto et al. (1997) 
Plant .1. 12(2)1255-265; KaWamata et al. (1997) Plant Cell 
Physiol. 38(7)1792-803; Hansen et al. (1997) Mol. Gen. 
Genet. 254(3)1337-343; Russell et al. (1997) Transgenic Res. 
6(2)1157-168; Rinehart et al. (1996) Plant Physiol. 112(3): 
1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2): 
525-535; Canevascini et al. (1996) Plant Physiol. 112(2): 
513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5): 
773-778; Lam (1994) Results Probl. Cell Di?‘er. 201181-196; 
OroZco et al. (1993) Plant Mol Biol. 23(6)11129-1138; Mat 
suoka et al. (1993) Proc Natl. Acad. Sci. USA 90(20)19586 
9590; and Guevara-Garcia et al. (1993) Plant.]. 4(3)1495-505. 
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Of particular interest herein are leaf preferred promoters 
that provide for expression predominately in leaf tissues. See, 
e.g., Yamamoto et al. (1997)PlantJ. 12(2):255-265; KWon et 
al. (1994) Plant Physiol. 105:357-67;Yamamoto et al. (1994) 
Plant Cell Physiol. 35(5):773-778; Gotor et al. (1993) Plant 
J. 3:509-18; OroZco et al. (1993)PlantMol. Biol. 23(6):1 129 
1138; BasZcZynski et al. (1988) Nucl. Acid Res. 16:4732; 
Mitra et al. (1994) Plant Molecular Biology 26:35-93; 
Kayaya et al. (1995) Molecular and General Genetics 248: 
668-674; and Matsuoka et al. (1993) Proc. Natl. Acad. Sci. 
USA 90(20):9586-9590. Senecence-regulated et al. (1998) 
Plant Physiol. 116:329-335); SAG 13 (Gan and Amasino 
(1997) Plant Physiol. 113:313-319; SAG 15 (Gan (1995) 
“Molecular Characterization and Genetic Manipulation of 
Plant Senescence,” Ph.D. Thesis, University of Wisconsin, 
Madison); SEN1 (Oh et al. (1996) Plant Mol. Biol. 30:739 
754; promoter of a senescence-speci?c gene for expression of 
IPT (Gan and Amasino 91995) Science 270: 1 986-1988); and 
the like (see, e.g., Or et al. (1999) Plant Cell 11: 1073-1080; 
and McCabe et al. (2001) Plant Physiol. 127:505-516). 
Expression cassettes of the present invention can include 5' 
leader sequences that can act to enhance translation. Transla 
tion leaders are knoWn in the art and include, but are not 
limited to, picornavirus leaders, e.g., EMCV leader (En 
cephalomyocarditis 5' noncoding region; Elroy-Stein et al. 
(1989) Proc. Natl. Acid. Sci. USA 86:6126-6130); potyvirus 
leaders, e.g., TEV leader (Tobacco Etch Virus; Gallie et al. 
(1995) Gene 165(2):233-238), MDMV leader (MaiZe Dwarf 
Mosaic Virus; I/irology 154:9-20), and human immunoglo 
bulin heavy-chain binding protein (BiP; Macej ak et al. (1991) 
Nature 353:90-94); untranslated leader from the coat protein 
mRNA of alfalfa mosaic virus (AMV RNA 4; Jobling et al. 
(1987) Nature 325:622-625); tobacco mosaic virus leader 
(TMV; Gallie et al. (1989) in Molecular biology ofRNA, ed. 
Cech (Liss, NeW York), pp. 237-256); and maiZe chlorotic 
mottle virus leader (MCMV; Lommel et al. (1991) I/irology 
81 :382-385). See also, Della-Cioppa et al. (1987) Plant 
Physiol. 84:965-968. Other methods knoWn to enhance trans 
lation also can be utiliZed. 
Methods for Inhibiting Expression or Function of a Nicotine 
Demethylase 
Methods of reducing the concentration, content and/or 
activity of a cytochrome P450 polypeptide of the present 
invention in a Nicotiana plant or plant part, particularly the 
leaf tissue, are provided. Many methods may be used, alone or 
in combination, to reduce or eliminate the activity of a cyto 
chrome P450 polypeptide of the present invention, more par 
ticularly, the CYP82E5v2 nicotine demethylase. In addition, 
combinations of methods may be employed to reduce or 
eliminate the activity of tWo or more different cytochrome 
P450 polypeptides, more particularly the CYP82E5v2 and 
CYP82E4v2 nicotine demethylases. Preferably, the 
CYP82E5v2 is a polypeptide With at least one amino acid 
mutation in SEQ ID NO:2 that negatively affects conversion 
in green leaves and the CYP82E4v2 has the sequence set forth 
in SEQ ID NO:13 With at least one amino acid mutation that 
negatively affects conversion in senescent leaves. 
In accordance With the present invention, the expression of 
a cytochrome P450 polypeptide of the present invention is 
inhibited if the protein level of the cytochrome P450 polypep 
tide is statistically loWer than the protein level of the same 
cytochrome P450 polypeptide in a plant that has not been 
genetically modi?ed or mutageniZed to inhibit the expression 
of that cytochrome P450 polypeptide, and Where these plants 
have been cultured and harvested using the same protocols. In 
particular embodiments of the invention, the protein level of 












ing to the invention is less than 95%, less than 90%, less than 
80%, less than 70%, less than 60%, less than 50%, less than 
40%, less than 30%, less than 20%, less than 10%, or less than 
5% of the protein level of the same cytochrome P450 
polypeptide in a plant that is not a mutant or that has not been 
genetically modi?ed to inhibit the expression of that cyto 
chrome P450 polypeptide and Which has been cultured and 
harvested using the same protocols. The expression level of 
the cytochrome P450 polypeptide may be measured directly, 
for example, by assaying for the level of the cytochrome P450 
transcript or cytochrome P450 polypeptide expressed in the 
Nicotiana plant or plant part, or indirectly, e.g., by measuring 
the conversion of nicotine to nomicotine in the Nicotiana 
plant or plant part. Methods for monitoring expression level 
of a polypeptide are knoWn in the art, and include, but are not 
limited to, Northern blot analysis and RNA differentiation 
assays. Methods for determining the activity of a targeted 
cytochrome P450 polypeptide in converting nicotine to nor 
nicotine are knoWn in the art and described elseWhere herein 
beloW, and include, but are not limited to, alkaloid analysis 
using gas chromatography. 
In some instances, the activity of one or more cytochrome 
P450 polypeptides is reduced or eliminated by transforming a 
plant or plant part With an expression cassette comprising a 
polynucleotide encoding a polypeptide that inhibits the activ 
ity of one or more cytochrome P450 polypeptides of the 
present invention. A number of approaches have been used to 
combine transgenes or mutations in one plantiincluding 
sexual crossing, retransformation, co-transformation and the 
use of linked transgenes. A chimeric transgene With linked 
partial gene sequences can be used to coordinately suppress 
numerous plant endogenous genes. Constructs modeled on 
viral polyproteins can be used to simultaneously introduce 
multiple coding genes into plant cells. For a revieW, see Hal 
pin et al., Plant Mol. Biol. 47:295-310 (2001). A plant having 
a mutation in CYP82E4v2 that inhibits the nicotine demethy 
lase activity in senescent leaves can be crossed With a plant 
having a mutation in CYP83E5v2 that inhibits nicotine dem 
ethylase in green leaves to produce a plant With conversion 
levels loWer than about 0.2%, 0.3%, 0.4%, 0.5%, 0.6% or 
0.7%. Alternatively, a plant having one or more mutations in 
CYP82E4v2 atposition 458, 364, 38, 201, 169, 459, 296, 427, 
329, 376 or 171 can be crossed With a plant having one or 
more mutations in CYP83E5v2 at position 235, 449, 174, 
410, 224, 72 or 143 to produce a plant With conversion levels 
loWer than 0.2%, 0.3%, 0.4%, 0.5%, 0.6% or 0.7%. Altema 
tively still, a plant having one or more mutations in 
CYP82E4v2 at position 458, 364 or 329 can be crossed With 
a plant having one or more mutations in CYP83E5v2 at 
position 235,449, 174, 410, 224, 72, or 143 to produce a plant 
With conversion levels loWer than 0.2%, 0.3%, 0.4%, 0.5%, 
0.6%, or 0.7%. A particularly preferred conversion level of 
nicotine to nomicotine can be betWeen 0.05%-0.4%, between 
01-06%, betWeen 0.1%-0.3%, betWeen 0.1%-0.5%, 
betWeen 0.1%-0.4%, betWeen 0.1%-0.7%, or betWeen 0.1% 
1 .0%. Any mutation of a polynucleotide of the present inven 
tion that results in a truncation of the CYP83E4v2 or 
CYP83E5v2 polypeptide before a conserved heme-binding 
motif Will inhibit the enzyme and can be used in a cross 
described above. The domains of cytochrome P450 proteins 
are knoWn in the art. See, e.g., Xu et al. (2007) Physiologia 
Plantarum 129:307-319, incorporated herein by reference as 
if set forth in its entirety. By crossing plants having a non 
functional or inhibited CYP82E4v2 gene, a nonfunctional or 
inhibited CYP82E5v2 gene, or nonfunctional or inhibited 
CYP82E4v2 and CYP82E5v2 genes, nornicotine levels can 
be reduced in a tobacco plant. 
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The activity of a nicotine demethylase polypeptide in con 
verting nicotine to nornicotine in a Nicoliana plant or plant 
part is inhibited according to the present invention if this 
conversion activity is statistically loWer than conversion 
activity of the same cytochrome P450 polypeptide in a Nic 
oliana plant or plant part that has not been genetically modi 
?ed to inhibit the conversion activity of that cytochrome P450 
polypeptide and that has been cultured and harvested using 
the same protocols. In particular embodiments, activity of a 
cytochrome P450 polypeptide in converting nicotine to nor 
nicotine in a modi?ed Nicoliana plant or plant part according 
to the invention is inhibited if the activity is less than 95%, 
less than 90%, less than 80% less than 70%, less than 60%, 
less than 50%, less than 40%, less than 30%, less than 20% 
less than 10%, less than 5%, less than 2% or less than 1% of 
the conversion activity of the same cytochrome P450 
polypeptide in a Nicoliana plant that that has not been geneti 
cally modi?ed to inhibit the expression of that nicotine dem 
ethylase polypeptide and that has been cultured and harvested 
using the same protocols. The activity of a nicotine demethy 
lase polypeptide in converting nicotine to nomicotine in a 
Nicoliana plant or plant part is eliminated according to the 
invention When it is not detectable by the assay methods 
knoWn in the art or described herein. Methods of determining 
the activity of a cytochrome P450 polypeptide in converting 
nicotine to nomicotine in a Nicoliana using gas chromatog 
raphy are disclosed in the examples beloW. 
In speci?c embodiments, a cytochrome P450 inhibitory 
polynucleotide or nicotine demethylase mutation described 
herein is introduced into a Nicoliana plant or plant part. 
Subsequently, a Nicoliana plant orplant part having the intro 
duced inhibiting polynucleotide of the present invention is 
selected using methods knoWn to those of skill in the art 
including, but not limited to, Southern blot analysis, DNA 
sequencing, PCR analysis or phenotypic analysis. A poly 
nucleotide or polypeptide sequence of the present invention 
includes full-length polynucleotide or polypeptide 
sequences, truncated polynucleotide or polypeptide 
sequences, fragments of polynucleotide or polypeptide 
sequences, variants of polynucleotide or polypeptide 
sequences, sense-oriented nucleotide sequences, antisense 
oriented nucleotide sequences, the complement of a sense- or 
antisense-oriented nucleotide sequence, inverted regions of 
nucleotide sequences, hairpins of nucleotide sequences, 
double-stranded nucleotide sequences, single-stranded 
nucleotide sequences, combinations thereof, and the like. A 
plant or plant part altered or modi?ed by the foregoing is 
groWn under plant-forming conditions for a time su?icient to 
modulate the concentration and/or activity of polypeptides of 
the present invention in the plant. Plant forming conditions 
are Well knoWn in the art and discussed brie?y elseWhere 
herein. 
A transformed tobacco plant containing a nicotine dem 
ethylase inhibitory polynucleotide sequence described herein 
has a reduced level of conversion of nicotine to nornicotine. In 
particular embodiments, conversion of nicotine to nomico 
tine in a tranformed tobacco plant or plant part according to 
the invention is less than 95%, less than 90%, less than 80% 
less than 70%, less than 60%, less than 50%, less than 40%, 
less than 30%, less than 20%, less than 10%, less than 5%, 
less than 2% or less than 1% of the conversion in a tobacco 
plant that that has not been genetically modi?ed to inhibit the 
expression of that nicotine demethylase polypeptide and With 
has been cultured and harvested using the same protocols. In 
some instances, the transformed tobacco plant is a converter 
tobacco plant. Alternatively, the transformed tobacco plant is 












formed tobacco plant has a conversion rate loWer than the rate 
observed in commercial non-converter tobacco plants. 
The level and/ or activity of the polypeptide may be modu 
lated by employing a polynucleotide that is not capable of 
directing, in a transformed plant, the expression of a protein 
or an RNA. For example, the polynucleotides of the invention 
may be used to design polynucleotide constructs that can be 
employed in methods for altering or mutating a genomic 
nucleotide sequence in an organism. Such polynucleotide 
constructs include, but are not limited to, RNAzDNA vectors, 
RNAzDNA mutational vectors, RNAzDNA repair vectors, 
mixed-duplex oligonucleotides, self-complementary RNA: 
DNA oligonucleotides and recombinogenic oligonucleo 
bases. Such nucleotide constructs and methods of use are 
knoWn in the art. See, US. Pat. Nos. 5,565,350; 5,731,181; 
5,756,325; 5,760,012; 5,795,972 and 5,871,984; each of 
Which is incorporated herein by reference as if set forth in its 
entirety. See also, International Patent Application Publica 
tion Nos. WO 98/149350, WO 99/107865 and WO 
99/125921; and Beetham et al. (1999) Proc. Natl. Acad. Sci. 
USA 96:8774-8778; each of Which is incorporated herein by 
reference as if set forth in its entirety. 
The methods of the present invention do not depend on the 
incorporation of the entire nicotine demethylase inhibitory 
polynucleotide into the genome, only that the Nicoliana plant 
or plant part thereof is altered as a result of the introduction of 
this inhibitory polynucleotide into a cell. As such, the genome 
may be altered folloWing the introduction of the nicotine 
demethylase inhibitory polynucleotide into a cell. For 
example, the inhibitory polynucleotide, or any part thereof, 
may incorporate into the genome of the plant. Alterations to 
the genome include, but are not limited to, additions, dele 
tions and substitutions of nucleotides into the genome. While 
the methods of the present invention do not depend on addi 
tions, deletions and substitutions of any particular number of 
nucleotides, it is recogniZed that such additions, deletions 
and/or substitutions comprise at least one nucleotide. 
Further, one can reduce the level and/ or activity of a nico 
tine demethylase sequence by eliciting the effects of the 
sequence only during certain developmental stages and to 
sWitch the effect off in other stages Where expression is no 
longer desirable. Control of nicotine demethylase expression 
can be obtained via the use of inducible or tissue-preferred 
promoters. Alternatively, the gene could be inverted or 
deleted using site-speci?c recombinases, transposons or 
recombination systems, Which Would also turn on or off 
expression of the cytochrome P450 sequence. 
According to the present invention, changes in levels, 
ratios, activity or distribution of cytochrome P450 polypep 
tides of the present invention, or changes in N icoliana plant or 
plant part phenotype, particularly reduced accumulation of 
nornicotine and its carcinogenic metabolite, NNN, can be 
measured by comparing a subject plant or plant part to a 
control plant or plant part, Where the subject plant or plant part 
and the control plant or plant part have been cultured and/or 
harvested using the same protocols. As used herein, a subject 
plant or plant part is one in Which genetic alteration, such as 
transformation, has been affected as to the nicotine demethy 
lase polypeptide of interest, or is a Nicoliana plant or plant 
part that is descended from a Nicoliana plant or plant part so 
altered and Which comprises the alteration. A control plant or 
plant part provides a reference point for measuring changes in 
phenotype of the subject plant or plant part. The measurement 
of changes in phenotype can be measured at any time in a 
plant or plant part, including during plant development, 
senescence, or after curing. In other embodiments, the mea 
surement of changes in phenotype can be measured in plants 
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grown under any conditions, including from plants grown in 
growth chamber, greenhouse, or in a ?eld. In one embodi 
ment, changes in phenotype can be measured by determining 
the nicotine to nornicotine conversion rate. In a preferred 
embodiment, conversion can be measured by dividing the 
percentage of nornicotine (as a percentage of the total tissue 
weight) by the sum of the percentage nicotine and nornicotine 
(as percentages of the total tissue weight) and multiplying by 
100. 
According to the present invention, a control plant or plant 
part may comprise a wild-type Nicoliana plant or plant part, 
i.e., of the same genotype as the starting material for the 
genetic alteration that resulted in the subject plant or plant 
part. A control plant or plant part may also comprise a Nic 
oliana plant or plant part of the same genotype as the starting 
material but that has been transformed with a null construct 
(i.e., with a construct that has no known effect on the trait of 
interest, such as a construct comprising a selectable marker 
gene). Alternatively, a control plant or plan part may comprise 
a Nicoliana plant or plant part that is a non-transformed 
segregant among progeny of a subject plant or plant part, or a 
Nicoliana plant or plant part genetically identical to the sub 
ject plant or plant part but that is not exposed to conditions or 
stimuli that would induce suppression of the nicotine dem 
ethylase gene of interest. Finally, a control plant or plant part 
may comprise the subject plant or plant part itself under 
conditions in which the nicotine demethylase inhibitory 
sequence is not expressed. In all such cases, the subject plant 
or plant part and the control plant or plant part are cultured 
and harvested using the same protocols. 
As described elsewhere herein, methods are provided to 
reduce or eliminate the activity and/or concentration of a 
nicotine demethylase polypeptide of the present invention by 
introducing into a Nicoliana plant or plant part a nicotine 
demethylase inhibitory polynucleotide sequence than is 
capable of inhibiting expression or function of a nicotine 
demethylase polypeptide that is involved in the metabolic 
conversion of nicotine to nornicotine. In some instances, the 
inhibitory sequence can be introduced by transformation of 
the plant or plant part such as a plant cell with an expression 
cassette that expresses a polynucleotide that inhibits the 
expression of the nicotine demethylase polypeptide. The 
polynucleotide may inhibit the expression of a nicotine dem 
ethylase polypeptide directly, by preventing translation of the 
nicotine demethylase polypeptide messenger RNA, or indi 
rectly, by encoding a polypeptide that inhibits the transcrip 
tion or translation of a nicotine demethylase polypeptide gene 
encoding a nicotine demethylase polypeptide. Methods for 
inhibiting or eliminating the expression of a gene product in 
a plant are well known in the art, and any such method may be 
used in the present invention to inhibit the expression of 
nicotine demethylase polypeptides. 
In other embodiments, the activity of a nicotine demethy 
lase polypeptide of the present invention may be reduced or 
eliminated by disrupting the gene encoding the nicotine dem 
ethylase polypeptide. The invention encompasses 
mutageniZed plants that carry mutations in cytochrome P450 
genes, where the mutations reduce expression of the nicotine 
demethylase gene or inhibit the activity of an encoded nico 
tine demethylase polypeptide of the present invention. 
To obtain the desired plants, a Nicoliana plant or plant part 
can be transformed with an expression cassette that is capable 
of expressing a polynucleotide that inhibits the expression of 
a nicotine demethylase sequence. Such methods may include 
the use of sense suppression/cosuppression, antisense sup 
pression, double-stranded RNA (dsRNA) interference, hair 












interference, amplicon-mediated interference, riboZymes, 
and small interfering RNA or micro RNA. 
For cosuppression, an expression cassette is designed to 
express an RNA molecule corresponding to all or part of a 
messenger RNA encoding a cytochrome P450 polypeptide of 
interest (for example, a cytochrome P450 polypeptide com 
prising the sequence set forth in SEQ ID NO:2 or 5-24 or a 
sequence having substantial sequence identity to SEQ ID 
NO:2 or 5-24) in the “sense” orientation. Over-expression of 
the RNA molecule can result in reduced expression of the 
native gene. Multiple plant lines transformed with the cosup 
pression expression cassette are then screened to identify 
those that show the greatest inhibition of nicotine demethy 
lase polypeptide expression. 
The polynucleotide used for cosuppression may corre 
spond to all or part of the sequence encoding a cytochrome 
P450 polypeptide or the present invention, all or part of the 5' 
and/or 3' untranslated region of a cytochrome P450 polypep 
tide transcript, or all or part of both the coding sequence and 
the untranslated regions of a transcript encoding a cyto 
chrome P450 polypeptide. In some embodiments where the 
polynucleotide comprises all or part of the coding region for 
a cytochrome P450 polypeptide of the present invention, the 
expression cassette can be designed to eliminate the start 
codon of the polynucleotide so that no polypeptide product 
will be transcribed. 
Cosuppression may be used to inhibit the expression of 
plant genes to produce plants having undetectable levels for 
the polypeptides encoded by these genes or may also be used 
to inhibit the expression of multiple proteins in the same plant 
(e.g., Broin et al. (2002) Plant Cell 14:1417-1432; and US. 
Pat. No. 5,942,657). Methods for using cosuppression to 
inhibit the expression of endogenous genes in plants are 
described in Flavell et al. (1994) Proc Natl. Acad. Sci. USA 
91:3490-3496; Jorgensen et al. (1996) Plant Mol. Biol. 
31:957-973; Johansen and Carrington (2001) Plant Physiol. 
126:930-938; Brain et al. (2002) Plant Cell 14:1417-1432; 
Stoutjesdijk et al. (2002) PlanZPhysiol. 129: 1723-1731 ;Yu et 
al. (2003) Phylochemislry 631753-763; and US. Pat. Nos. 
5,034,323; 5,283,184 and 5,942,657; each ofwhich is incor 
porated herein by reference as if set forth in its entirety. The 
ef?ciency of cosuppression may be increased by including a 
poly-dT region in the expression cassette at a position 3' to the 
sense sequence and 5' of the polyadenylation signal. See, US 
Patent Application Publication No. 2002/0048814, incorpo 
rated herein by reference as if set forth in its entirety. Typi 
cally, such a nucleotide sequence has substantial sequence 
identity to the sequence of the transcript of the endogenous 
gene, preferably greater than about 65% sequence identity, 
more preferably greater than about 95% sequence identity, 
most preferably greater than about 99% sequence identity 
(e.g., US. Pat. Nos. 5,283,184 and 5,034,323; incorporated 
herein by reference as if set forth in its entirety). 
Inhibition of the expression of the cytochrome P450 
polypeptide of the present invention also can be obtained by 
antisense suppression. For antisense suppression, the expres 
sion cassette is designed to express an RNA molecule 
complementary to all or part of a messenger RNA encoding 
the cytochrome P450 polypeptide. Over-expression of the 
antisense RNA molecule can result in reduced expression of 
the native gene. Accordingly, multiple plant lines transformed 
with the antisense suppression expression cassette are 
screened to identify those that show the greatest inhibition of 
nicotine demethylase polypeptide expression. 
The polynucleotide for use in antisense suppression may 
correspond to all or part of the complement of the sequence 
encoding the cytochrome P450 polypeptide, all or part of the 
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complement of the 5' and/or 3' untranslated region of the 
cytochrome P450 polypeptide transcript, or all or part of the 
complement of both the coding sequence and the untranslated 
regions of a transcript encoding the cytochrome P450 
polypeptide. In addition, the antisense polynucleotide may be 
fully complementary (i.e., 100% identical to the complement 
of the target sequence) or partially complementary (i.e., less 
than 100% identical to the complement of the target 
sequence) to the target sequence. 
Antisense suppression also can be used to inhibit the 
expression of multiple proteins in the same plant (e.g., U.S. 
Pat. No. 5,942,657). Furthermore, portions of the antisense 
nucleotides may be used to disrupt the expression of the target 
gene. Generally, sequences of at least 50 nucleic acids, 100, 
200, 300, 400, 450, 500, 550 nucleic acids, or greater may be 
used. Methods for using antisense suppression to inhibit the 
expression of endogenous genes in plants are described, e.g., 
in Liu et al. (2002) Plant Physiol. 129:1732-1743; and Us. 
Pat. Nos. 5,759,829 and 5,942,657; each of Which is incor 
porated herein by reference as if set forth in its entirety. 
E?iciency of antisense suppression may be increased by 
including a poly-dT region in the expression cassette at a 
position 3' to the antisense sequence and 5' of the polyadeny 
lation signal. See, US Patent Application Publication No. 
2002/0048814, incorporated herein by reference as if set forth 
in its entirety. 
For dsRNA interference, a sense RNA molecule like that 
described above for cosuppression and an antisense RNA 
molecule that is fully or partially complementary to the sense 
RNA molecule are expressed in the, same cell, resulting in 
inhibition of the expression of the corresponding endogenous 
messenger RNA. Expression of the sense and antisense mol 
ecules can be accomplished by designing the expression cas 
sette to comprise both a sense sequence and an antisense 
sequence for the target cytochrome P450 sequence. Alterna 
tively, separate expression cassettes may be used for the sense 
and antisense sequences. Multiple plant lines transformed 
With the dsRNA interference expression cassette or expres 
sion cassettes are then screened to identify plant lines that 
shoW the greatest inhibition of expression of the targeted 
cytochrome P450 polypeptide. Methods for using dsRNA 
interference to inhibit the expression of endogenous plant 
genes are described in Waterhouse et al. (1998) Pros. Natl. 
Acad. Sci. USA 95:13939-13964; Liu et al. (2002) Plant 
Physiol. 129:1732'-1743; and International Patent Applica 
tion Publication Nos. WO 99/149024, WO 99/153050, WO 
99/16163 1 and WO 00/149035; each of Which is incorpo 
rated herein by reference as if set forth in its entirety. 
Amplicon expression cassettes comprise a plant virus-de 
rived sequence that contains all or part of the target gene but 
generally not all of the genes of the native virus. The viral 
sequences present in the transcription product of the expres 
sion cassette alloW the transcription product to direct its oWn 
replication. The transcripts produced by the amplicon may be 
either sense or antisense relative to the target sequence (i.e., 
the messenger RNA for a cytochrome P450 polypeptide that 
is involved in the metabolic conversion of nicotine to norni 
cotine). Methods of using amplicons to inhibit the expression 
of endogenous plant genes are described, e.g., in Angell & 
Baulcombe (1997) EMBO .1. 16:3675-3684; Angell & Baul 
combe (1999) Plant.]. 201357-362; and Us. Pat. No. 6,646, 
805, each of Which is incorporated herein by reference as if set 
forth in its entirety. 
In some instances, the polynucleotide expressed by the 
expression cassette of the invention is catalytic RNA or has 
riboZyme activity speci?c for the messenger RNA of a cyto 












nucleotide causes the degradation of the endogenous messen 
ger RNA, resulting in reduced expression of the cytochrome 
P450 polypeptide. This method is described, for example, in 
Us. Pat. No. 4,987,071, incorporated herein by reference as 
if set forth in its entirety. 
In other instances, inhibition of the expression of one or 
more nicotine demethylase polypeptides may be obtained by 
RNA interference by expression of a gene encoding a micro 
RNA (miRNA). miRNAs are regulatory agents consisting of 
about tWenty-tWo ribonucleotides. miRNA are highly e?i 
cient at inhibiting the expression of endogenous genes. See, 
e.g., Javier et al. (2003) Nature 425:257-263, incorporated 
herein by reference as if set forth in its entirety. 
For miRNA interference, the expression cassette is 
designed to express an RNA molecule that is modeled on an 
endogenous miRNA gene. The miRNA gene encodes an 
RNA that forms a hairpin structure containing a 22-nucle 
otide sequence that is complementary to another endogenous 
gene (target sequence). For suppression of nicotine demethy 
lase polypeptide expression, the 22-nucleotide sequence is 
selected from a cytochrome P450 polypeptide transcript 
sequence and contains 22 nucleotides encoding this cyto 
chrome P450 polypeptide sequence in sense orientation and 
21 nucleotides of a corresponding antisense sequence that is 
complementary to the sense sequence. miRNA molecules are 
highly e?icient at inhibiting the expression of endogenous 
genes, and the RNA interference they induce is inherited by 
subsequent generations of plants. 
Alternatively still, inhibition of the expression of one or 
more cytochrome P450 polypeptides may be obtained by 
hairpin RNA (hpRNA) interference or intron-containing hair 
pin RNA (ihpRNA) interference. These methods are highly 
e?icient at inhibiting the expression of endogenous genes. 
See, Waterhouse & HelliWell (20013) Nat. Rev. Genet. 4:29 
38 and the references cited therein. 
The expression cassette for hpRNA interference may also 
be designed such that the sense sequence and the antisense 
sequence do not correspond to an endogenous RNA in this 
embodiment, the sense and antisense sequence ?ank a loop 
sequence that comprises a nucleotide sequence correspond 
ing to all or part of the endogenous messenger RNA of the 
target gene. Thus, it is the loop region that determines the 
speci?city of the RNA interference. See, e.g., International 
Patent Application Publication No. WO 02/00904, incorpo 
rated herein by reference as if set forth in its entirety. 
Transcriptional gene silencing (TGS) may be accom 
plished through use of hpRNA constructs Where the inverted 
repeat of the hairpin shares sequence identity With the pro 
moter region of a gene to be silenced. Processing of the 
hpRNA into short RNAs that can interact With the homolo 
gous promoter region may trigger degradation or methylation 
to result in silencing (AufsatZ et al. (2002) Proc. Natl. Acad. 
Sci. 99:16499-16506; and Mette et al. (2000) EMBO J. 
19:5194-5201). 
In some instances, the polynucleotide encodes an antibody 
that binds to at least one cytochrome P450 polypeptide, and 
reduces the activity of a cytochrome P450 polypeptide of the 
present invention. In another embodiment, the binding of the 
antibody results in increased turnover of the antibody-cyto 
chrome P450 polypeptide complex by cellular quality control 
mechanisms. The expression of antibodies in plant parts and 
the inhibition of molecular pathWays by expression and bind 
ing of antibodies to proteins in plant parts are Well knoWn in 
the art. See, e.g., Conrad & SonneWald (2003) Nature Bio 
tech. 21 :35-36, incorporated herein by reference as if set forth 
in its entirety. 
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The activity of a cytochrome P450 polypeptide of the 
present invention can be reduced or eliminated by disrupting 
the gene encoding the cytochrome P450 polypeptide. The 
gene encoding the cytochrome P450 polypeptide may be 
disrupted by any method knoWn in the art, e. g., by transposon 
tagging or by mutageniZing plants using random or targeted 
mutagenesis and selecting for plants that have reduced nico 
tine demethylase activity or mutations in CYP82E4v2 or 
CYP82E5v2. 
Transposon tagging may be used to reduce or eliminate the 
activity of one or more cytochrome P450 polypeptides of the 
present invention. Transposon tagging comprises inserting a 
transposon Within an endogenous cytochrome P450 gene to 
reduce or eliminate expression of the cytochrome P450 
polypeptide. 
Methods for the transposon tagging of speci?c genes in 
plants are Well knoWn in the art. See, e.g., Maes et al., (1999) 
Trends Plant Sci. 4:90-96; Dharmapuri & Sonti (1999) 
FEMSMicerobiol. Lett. 179:53-59; Meissner et al. (2000) 
Plant.]. 22:265-274; Phogat et al. (2000) J Biosci. 25:57-63; 
Walbot (2000) Curr. Opin. Plant Biol. 2:103-107; Gai et al. 
(2000) Nucleic Acids Res. 28:94-96; and Fitzmaurice et al. 
(1999) Genetics 153:1919-1928). 
Additional methods for decreasing or eliminating the 
expression of endogenous genes in plants are also knoWn in 
the art and can be similarly applied to the instant invention. 
These methods include other forms of mutagenesis, using 
mutagenic or carcinogenic compounds including ethyl meth 
anesulfonate-induced mutagenesis, deletion mutagenesis, 
and fast neutron deletion mutagenesis used in a reverse genet 
ics sense (With PCR) to identify plant lines in Which the 
endogenous gene has been deleted. For examples of these 
methods see, Ohshima et al. (1998) Wrology 213:472-481; 
Okubara et al. (1994) Genetics 137:867-874; and Quesada et 
al. (2000) Genetics 154:421-4315; each ofWhich is incorpo 
rated herein by reference as if set forth in its entirety. In 
addition, a fast and automatable method for screening for 
chemically induced mutations, TILLING (Targeting Induced 
Local Lesions In Genomes), using denaturing HPLC or selec 
tive endonuclease digestion of selected PCR products is also 
applicable to the instant invention. See, McCallum et al. 
(2000) Nat. Biotechnol. 18:455-457, herein incorporated by 
reference. 
Mutations that impact gene expression or that interfere 
With the function of the encoded cytochrome P450 protein 
can be determined using methods that are Well knoWn in the 
art. Insertional mutations in gene exons usually result in null 
mutants. Mutations in conserved residues can be particularly 
effective in inhibiting the metabolic function of the encoded 
protein. Conserved residues of plant cytochrome P450 
polypeptides suitable for mutagenesis With the goal to elimi 
nate activity of a cytochrome P450 polypeptide in converting 
nicotine to nornicotine in a Nicotiana plant or plant part have 
been described. Conserved residues of plant cytochrome 
P450 polypeptides are disclosed in FIG. lA-C, Where the 
residues that differ from the other P450 polypeptides are 
shaded in grey. The conserved residue is that Which is not 
shaded in grey at each position. Such mutants can be isolated 
according to Well-knoWn procedures. 
Dominant mutants can be used to trigger RNA silencing 
due to gene inversion and recombination of a duplicated gene 
locus. See, e.g., Kusaba et al. (2003) Plant Cell 15:1455 
1467. 
While a number of sequences are recogniZed in the practice 
of the invention, in particular sequences encoding SEQ ID 
NO:2 and 13 ?nd particular use. While not intending to be 












believed that these sequences encode a nicotine demethylase 
that catalyZes the oxidative N-demethylation of nicotine to 
nornicotine. Thus, methods to speci?cally inhibit these cod 
ing sequences and not other P450 sequences may be bene? 
cial to the recombinant plant. That is, strategies that Would 
lead to inhibition of gene function of this individual locus 
may prove to be superior to those that inhibit the entire gene 
family. The P450 enZymes are involved in many mechanisms 
in the plant, the inhibition of Which may prove deleterious or 
detrimental to the groWth and development of the plant or 
may negatively impact factors such as the disease defense 
capabilities of the plant. Likewise, because the Nicotiana 
plant P450 enZymes have been implicated in plant metabo 
lites such as phenylpropanoid, alkaloids, terpenoids, lipids, 
cyanogenic glycosides, glucosinolates, and a host of other 
chemical entities, disruption of P450 activity may alter com 
ponents involved in tobacco ?avor, texture, or other proper 
ties that Would impact the commercial usefulness of the plant. 
Therefore, the use of the methods discussed above to inhibit 
expression in a manner that speci?cally targets the sequence 
coding for SEQ ID NO:2 or 13 may be preferred, including 
targeted mutational strategies, such as chimeraplasty. See, 
e.g., SteWart et al. (2000) Biotechniques 24:838-843; and 
Graham et al. (2002) Biochim BiophysActa 1587: 1-6; each of 
Which is incorporated herein by reference as if set forth in its 
entirety. In some embodiments, the methods discussed above 
are used to inhibit expression in a manner that speci?cally 
targets SEQ ID NO:1 (encoding SEQ ID NO:2), SEQ ID 
NO:50 (encoding SEQ ID NO: 13), or both of these 
sequences. 
The compositions of the invention can be used in screening 
methods to identify nonconverter plants for use in breeding 
programs. In this manner, the nucleotide sequences of the 
invention can be used to screen native germplasms for non 
converter plants having a stable mutation in one or more P450 
genes identi?ed herein. These nonconverter plants identi?ed 
by the methods of the invention can be used to develop breed 
ing lines. 
In addition to the nucleotide sequences encoding P450 
coding sequences, compositions of the invention include an 
intron sequence in the CYP82E5v2 sequence that can be used 
in screening methods. While not intending to be bound by any 
particular mechanism of action, the CYP82E5v2 gene(s) may 
represent the only member(s) of the cytochrome P450 family 
involved in the metabolic conversion of nicotine to nomico 
tine (and as stated previously there is a good likelihood that 
the CYP82E5v2 cDNAs originated from a single unique 
genetic locus) in green-leaves of tobacco. For certain appli 
cations, it Would be useful to have a means of diagnostically 
differentiating this speci?c member of the cytochrome P450 
gene family from the rest of the closely related sequences 
Within this family. For example, it is possible that Within the 
naturally existing tobacco ger'mplasm (or in mutageniZed 
populations), accessions may exist in Which this gene is natu 
rally dysfunctional and may therefore may be valuable as a 
permanently nonconverter resource. Such dysfunctional 
genes may include those encoding the polypeptides set forth 
in SEQ ID NOS:6 and 12. A method to speci?cally assay for 
such genotypes (e.g., deletion mutants, rearrangements, and 
the like) could serve as a poWerful tool. The present invention 
includes primers designed to speci?cally amplify exon 1 and 
exon 2 of CYP82E5v2 or CYP82E4v2 Where one of the tWo 
primer pairs corresponds to the intron betWeen the exons. 
Examples of primers useful to amplify the exons of 
CYP82E4v2 include SEQ ID NO:32 With SEQ ID NOS:33 
35. Examples of primers useful to amplify the exons of 
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CYP82E5v2 include SEQ ID NO136 With 37 and SEQ ID 
NO138 With 39. These same primers can be used for sequence 
analysis of the products. 
When any cDNA corresponding to a member of the 
CYP82E2 family is used as a hybridization probe in a South 
ern blotting assay of tobacco genome is DNA, a complex 
pattern is observed. This is expected, given that there are 
multiple, closely related members of this gene family. 
Because the intron regions of genes are typically less con 
served than exons, it is predicted that the use of an intron 
speci?c probe Would reduce this complexity and better enable 
one to distinguish the gene(s) corresponding to the 
CYP82E4v2 gene or the CYP82E5v2 gene from the other 
members of the family. The use of a CYP82E4v2 or 
CYP82E5v2 intron-speci?c probe, and/or the PCR primers 
used to generate products provide poWerful tools in assays to 
determine Whether any naturally occurring, or mutageniZed, 
tobacco plants possess deletions or rearrangements that may 
render the gene inactive. Such a plant can then be used in 
breeding programs to create tobacco lines that are incapable 
of converting. 
Transformed Plants, Plant Parts and Products Having 
Reduced Nornicotine and NNN Content 
The cytochrome P450 polynucleotides of the invention, 
and variants and fragments thereof, can be used in the meth 
ods of the present invention to inhibit cvtochrome P450s that 
are involved in the metabolic conversion of nicotine to nor 
nicotine in a plant. In this manner, inhibitory sequences that 
target expression or function of a cytochrome P450 polypep 
tide disclosed herein are introduced into a plant or plant cell of 
interest. The expression cassettes described herein can be 
introduced into a plant of interest, for example, a Nicotiana 
plant as noted herein beloW, using any suitable transformation 
methods knoWn in the art including those described herein. 
The methods of the invention do not depend on a particular 
method for introducing a sequence into a plant or plant part, 
only that the desired sequence gains access to the interior of at 
least one cell of the plant or plant part. Methods for introduc 
ing polynucleotide sequences into plants are knoWn in the art 
and include, but are not limited to, stable transformation 
methods, transient transformation methods and viral-medi 
ated transformation methods. 
Transformation protocols as Well as protocols for introduc 
ing heterologous polynucleotide sequences into plants vary 
depending on the type of plant or plant cell targeted for 
transformation. Suitable methods of introducing polynucle 
otides into plant cells of the present invention include micro 
injection (CrossWay et al. (1986) Biotechniques 41320-334), 
electroporation (Shillito et al. (1987) Meth. Enzymol. 153: 
313-336; and Riggs et al. (1986) Proc. Natl. Acad Sci. USA 
8315602-56116), A grobacterium-mediated transformation 
(US. Pat. Nos. 5,104,310; 5,149,645; 5,177,010; 5,231,019; 
5,463,174; 5,464,763; 5,469,976; 4,762,785; 5,004,863; 
5,159,135; 5,563,055 and 5,981,840), direct gene transfer 
(PasZkoWski et al. (1984) EMBO .1. 112717-2722) and ballis 
tic particle acceleration (US. Pat. Nos. 4,945,050; 5,141,131 ; 
5,886,244; 5,879,918 and 5,932,782; Tomes et al. (1995) in 
Plant cell, tissue, and organ culture fundamental methods, ed. 
Gamborg & Phillips (Springer-Verlag, Berlin); McCabe et al. 
(1988) Biotechnology 61923-926). See also, Weissinger et al. 
(1988) Ann. Rev. Genet. 221421-477; Christou et al. (1988) 
Plant Physiol. 871671-674 (soybean); McCabe et al. (1988) 
Bio/Technology 61923-926 (soybean); Finer & McMullen 
(1991) In VlZI’O CellDev. Biol. 27P1175-182 (soybean); Singh 
et al. (1998) Theor. Appl. Genet. 961319-324 (soybean); De 
Wet et al. (1985) in The experimental manipulation ofovule 












(pollen); Kaeppler et al. (1 990) Plant CellReports 91415-418; 
and Kaeppler et al. (1992) Theo}: Appl. Genet, 841560-566 
(Whisker-mediated transformation); D’Halluin et al. (1992) 
Plant Cell 411495-1505 (electroporation); each of Which is 
incorporated herein by reference as if set forth in its entirety. 
Any plant tissue that can be subsequently propagated using 
clonal methods Whether by organogenesis or embryogenesis, 
may be transformed With a recombinant construct comprising 
a cytochrome P450 inhibitory sequence, for example, an 
expression cassette of the present invention. As used herein, 
“organogenesis” means a process by Which shoots and roots 
are developed sequentially from meristematic centers. As 
used herein, “embryogenesis” means a process by Which 
shoots and roots develop together in a concerted fashion (not 
sequentially), Whether from somatic cells or gametes. Exem 
plary tissues that are suitable for various transformation pro 
tocols described herein include, but are not limited to, callus 
tissue, existing meristematic tissue (e.g., apical meristems, 
axillary buds and root ineristems) and induced meristem tis 
sue (e.g., cotyledon meristem and hypocotyl meristem), 
hypocotyls, cotyledons, leaf disks, pollen, embryos and the 
like. 
As used herein, “stable transformation” means that the 
nucleotide construct of interest introduced into a plant inte 
grates into the genome of the plant and is capable of being 
inherited by the progeny thereof. Likewise, “transient trans 
formation” means that a sequence is introduced into the plant 
and is only temporally expressed or is only transiently present 
in the plant. 
The inhibitory sequences of the invention can be provided 
to a plant using a variety of transient transformation methods. 
The inhibitory sequences of the invention can be transiently 
transformed into the plant using techniques knoWn in the art. 
Such techniques include viral vector systems and the precipi 
tation of the polynucleotide in a manner that precludes sub 
sequent release of the DNA. Thus, the transcription from the 
particle-bound DNA can occur, but the frequency With Which 
it is released to become integrated into the genome is greatly 
reduced. Such methods include the use of particles coated 
With polyethyenlimine (PEI; Sigma 4P3143). 
Alternatively, the inhibitory sequence of the invention may 
be introduced into plants by contacting plants With a virus or 
viral nucleic acids. Generally, such methods involve incorpo 
rating an expression cassette of the invention Within a viral 
DNA or RNA molecule. Promoters for use in the expression 
cassettes of the invention also encompass promoters utiliZed 
for transcription by viral RNA polymerases. Methods for 
introducing polynucleotides into plants and expressing a pro 
tein encoded therein, involving viral DNA or RNA mol 
ecules, are knoWn in the art. See, e.g., US. Pat. Nos. 5,889, 
191; 5,889,190; 5,866,785; 5,589,367; 5,316,931; and Porta 
et al. (1996) Molecular Biotechnology 51209-221; each of 
Which is incorporated herein by reference as if set forth in its 
entirety. 
Transformed cells may be groWn into Nicotiana plants in 
accordance With conventional methods. See, e.g., Vasil & 
Hildebrandt (1965) Science 1501889; Negaard & Hoffman 
(1989) Biotechniques 7(8)1808-812. These plants may then 
be groWn, and either pollinated With the same transformed 
line or different lines, and the resulting progeny having 
expression of the desired phenotypic characteristic identi?ed, 
i.e., reduced expression of one or more nicotine demethylases 
that are involved in the metabolic conversion of nicotine to 
nornicotine, and thus reduced content of nornicotine, and a 
concomitant reduced content of its nitrosamine metabolite, 
NNN, in the plant, particularly in the leaf tissues. TWo or more 
generations may be groWn to ensure that expression of the 




















































